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Abstract 
 The behavioral effects of nicotine vary widely, yet investigation of the aversive 
effects of nicotine has been limited. A careful examination of how the aversive effects of 
nicotine results in punishment of behavior may contribute to the understanding of the 
control of behavior by nicotine. The overall goal of these studies was to develop 
punishment procedures to evaluate the aversive effects of intravenous nicotine in rats. 
Using punishment procedures, rats were trained to respond on a lever that delivered 
sucrose pellets, then the effects of response-independent and -dependent nicotine 
injections on sucrose-reinforced lever responding were examined. Manipulation of 
behavioral and pharmacological parameters included the dose of nicotine delivered per 
injection (0.01-0.18 mg/kg), the behavioral alternatives to punished responding 
(reinforced or non-reinforced), and the delay of scheduled nicotine delivery. Antagonist 
studies were also conducted to elucidate the role of nicotinic acetylcholine receptor(s) 
in mediating the punishing effects of nicotine. In general, sucrose was a reinforcer of 
lever responding, whereas nicotine dose-dependently decreased sucrose-reinforced 
lever responding, such that higher doses of nicotine were required to decrease lever 
responding when it was administered response-independently compared to its 
response-dependent delivery. Punishment by nicotine was attenuated if scheduled 
delivery of nicotine was delayed after a response, or if the behavioral alternative to 
punished responding did not deliver a positive reinforcer. While the punishing effects of 
nicotine are mediated by nicotinic acetylcholine receptors, the α4β2* subtype is not 
involved (as assessed by dihydro-beta-erythroidine administration). Punishment 
procedures can be used to study the aversive effects of nicotine in rats. Consideration 
of both the pharmacological and environmental conditions in which nicotine is self-
administered may be important in determining the more general behavioral effects of 
nicotine.  
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Chapter 1 
General Introduction 
 
Tobacco Epidemic 
 Tobacco smoking is the leading cause of preventable disease and premature 
death in the United States (US Department of Health and Human Services 2014). It is 
estimated that more than 16 million Americans suffer from a disease related to smoking 
such as cancer, cardiovascular disease, and diabetes, which contributes to over 
400,000 premature tobacco-related deaths a year in the United States. Despite the 
health consequences associated with tobacco smoking, over 40 million adults continue 
to smoke (Centers for Disease Control and Prevention 2014). While the determinants of 
tobacco addiction are multifaceted, nicotine, a constituent of tobacco, is considered 
“the drug in tobacco that causes addiction” (US Department of Health and Human 
Services 1988). 
 
Reinforcing Effects of Nicotine 
 Although it is recognized that the effects of nicotine that contribute to addiction 
are diverse, such as neuroadaptations that may occur with persistent use (e.g., 
tolerance and dependence) and withdrawal symptoms that may be experienced with 
cessation (see US Department of Health and Human Services 2010), the ability of 
nicotine to serve as a reinforcer (i.e., a stimulus that increases the probability of 
behavior that leads to its delivery) is widely regarded as a crucial property of nicotine 
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that supports the development and maintenance of the abuse of nicotine-containing 
products such as tobacco (Young and Herling 1986, Ator and Griffths 2003). A 
significant part of nicotine abuse research has therefore been devoted to examining the 
reinforcing effects of nicotine.  
 Preclinical intravenous (IV) drug self-administration procedures in which animals 
perform an operant response to obtain nicotine have been the standard by which the 
reinforcing effects of nicotine have been examined. The use and development of IV self-
administration procedures that clearly demonstrate the reinforcing effects of nicotine 
have been critical in the identification of pharmacological, genetic, and environmental 
determinants that may contribute to the development of nicotine abuse (see Perkins 
1999; Laviolette and van der Kooy 2004). However, while the reinforcing effects of IV 
nicotine have been demonstrated in rodents (e.g., Corrigall and Coen 1989; Donny et al. 
1995; Watkins et al. 1999), non-human primates (e.g., Goldberg et al. 1981; Le Foll et 
al. 2007), and humans (e.g., Harvey et al. 2004; Sofuoglu et al. 2008), establishing the 
reinforcing effects of nicotine in controlled studies remains difficult (see Le Foll and 
Goldberg 2009).  
 Procedures that facilitate reliable establishment and maintenance of nicotine 
self-administration require precise control of experimental parameters that include, but 
are not limited to, drug infusion durations that are rapid (Wakasa et al. 1995); delivering 
nicotine with drug paired stimuli (Goldberg et al. 1981; Chaudhri et al. 2005; 2006); and 
limiting access to nicotine through schedule control (Henningfield and Goldberg 1983b; 
Corrigall and Coen 1989), which seems to be most critical. For example, Goldberg and 
colleagues (1981) found that under second-order schedules of reinforcement, which 
both explicitly pair drug delivery with a specific stimulus and space drug availability 
through time, nicotine was a highly effective reinforcer and maintained rates and 
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patterns of behavior comparable to those maintained by cocaine in squirrel monkeys. In 
contrast, studies in which simple or continuous schedules of reinforcement were used 
either failed to establish self-administration of nicotine or maintained low response rates 
(see Griffiths et al. 1979). It was suggested by Goldberg and colleagues (1981) that 
using a second-order schedule ensured that injections were spaced at least 5 min 
apart, which was believed to mitigate the aversive/and or direct suppressant effects of 
nicotine when too frequent injections and/or large doses of nicotine were delivered.  
 Therefore, while self-administration procedures have been developed to 
demonstrate the reinforcing effects of IV nicotine, very specific conditions are often 
required to obtain such effects. Consequently, the reinforcing strength of nicotine (i.e., 
the likelihood that nicotine will function as a reinforcer under varying experimental 
conditions) has been considered weak relative to other drugs of abuse (Griffiths et al. 
1979; Dougherty et al. 1981; Henningfield and Goldberg 1983b; Collins 1990). For 
example, studies using IV self-administration procedures to compare the relative 
reinforcing strength of cocaine to nicotine found that nicotine either failed to establish, 
or maintained lower rates of self-administration behavior than cocaine (Pickens and 
Thompson 1968; Ator and Griffiths 1983; Risner and Goldberg 1983), and under 
concurrent (and mutually exclusive) schedules of drug self-administration, cocaine is 
preferred over nicotine (Manzardo et al. 2001).  
 
Aversive Effects of Nicotine 
 The limited conditions in which nicotine serves as a reinforcer may be related to 
the aversive effects of nicotine, that is, the stimulus effects of nicotine that cause an 
organism to behave so as to minimize exposure to nicotine (e.g., Benowitz 1990; Le Foll 
and Goldberg 2009). Studies using operant procedures to assess the aversive effects of 
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self-administered nicotine have been documented (Goldberg and Spealman 1982; 
1983, Spealman 1983; Henningfield and Goldberg 1983a). In these investigations of IV 
nicotine self-adminstration, it was noted that doses of nicotine that were reported to be 
reinforcing in squirrel monkeys could also function to punish food-reinforced lever 
responding (Goldberg and Spealman 1982; 1983) and to maintain lever responding to 
avoid its scheduled injection (Spealman 1983). Similarly, it has been reported that 
humans will also maintain responding to avoid IV injections of nicotine (Henningfield 
and Goldberg 1983a). These findings suggest that nicotine may have aversive effects 
that can control behavior. However, investigation of the aversive effects of nicotine 
using operant procedures beyond these early studies has been limited. Therefore, 
development of operant procedures to determine both the pharmacological and 
environmental factors that mediate the aversive effects of nicotine may contribute to a 
general understanding of how nicotine can control behavior.  
 
Neuronal Nicotinic Receptors and Behavioral Effects of Nicotine  
  It has been well documented that effects of nicotine are mediated through its 
agonist actions at nicotinic acetylcholine receptors (nAChRs) that are subdivided into 
muscle and neuronal subtypes (which is based on their major site of expression). And 
while actions at muscle nAChRs may mediate effects that contribute to the abuse of 
nicotine, it is the neuronal subtype that are found in both the peripheral and central 
nervous system (CNS) that are believed to be predominately involved in mediating the 
psychoactive effects of nicotine  (e.g., Gotti and Clementi 2004; Albuquerque et al. 
2009). The neuronal nAChRs are a functionally diverse group of ligand-gated ion 
channels that exist as pentamers made up of a combination of β (β2-β4) and/or α (α2-
α10) subunits. The possible combinations of subunits that can make up a receptor are 
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responsible for the different subtypes that exist, which differ in their pharmacological 
and kinetic properties (see Taly et al. 2009). Therefore, considerable efforts have been 
undertaken to determine the possible role of receptor subtype(s) in mediating specific 
each of behavioral effects of nicotine.  
 There is substantial evidence from behavioral studies using pharmacological 
and genetic techniques that demonstrate that the α4β2* subtype of nAChR are involved 
in mediating the reinforcing effects of nicotine (see in Picciotto and Kenny 2013). In 
behavioral pharmacological studies, treatment with dihydro-beta-erythroidine (DHβE), a 
competitive, α4β2* selective nAChR antagonists (Williams and Robinson, 1984; Sabey 
et al. 1999; Shoaib et al. 2000), has been shown to attenuate self-administration of 
nicotine in rats (Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 2000; Liu et 
al. 2007) and squirrel monkeys (Le Foll et al. 2009). In genetic studies, it has been 
shown that β2 knock-out (KO) mice that readily self-administer cocaine will not self-
administer nicotine (Picciotto et al. 1998), and that self-administration of nicotine could 
be established with targeted expression of β2 subunit gene into the ventral tegmental 
area (VTA) (Maskos et al. 2005), suggesting that β2* receptors are necessary for the 
maintenance of nicotine self-administration. Similar observations have been reported in 
α4 KO mice, such that nicotine self-administration is attenuated in α4 KO mice as 
compared to wild type mice, and increases in self-administration in α4 KO could be 
obtained with targeted re-expression of α4 subunit in the VTA (Pons et al. 2008). It 
should be noted that a limitation of genetic studies is the possibility of adaptations in 
neural circuitry that may affect the interpretation of the behavioral effects of nicotine. 
Therefore, these studies alone are not sufficient to indicate that the α4β2* nAChRs are 
involved in the reinforcing effects of nicotine, but in combination with studies using 
pharmacological techniques they do provide strong evidence to support the hypothesis 
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the α4β2* subtype of nAChR are involved in mediating the reinforcing effects of 
nicotine. 
 Interestingly, it has been suggested that α4β2* nAChRs may be involved in 
mediating the effects of nicotine-induced conditioned taste aversion (Shoaib and 
Stolerman 1995; Shoaib et al. 2000; 2002; Gommans et al. 2000) and nicotine-induced 
conditioned place aversion (Laviolette and van der Kooy 2003). However, it should be 
noted that a limitation of these findings is that these procedures provide an indirect 
measurement of the aversive effects of nicotine because they do not measure drug-
taking behaviors. Pharmacological studies using operant procedures have 
demonstrated that nAChRs mediate the aversive effects of nicotine such that treatment 
with mecamylamine, a non-selective nAChR antagonist, is able to dose-dependently 
block the punishing effects of nicotine (Goldberg and Spealman 1982). Additionally it 
has been suggested that the aversive effects of nicotine are likely being mediated by 
nAChRs in the CNS since hexamethonium, a nicotinic antagonist with primarily 
peripheral effects, was not able to attenuate the aversive effects of nicotine that 
maintained responding to postpone delivery of IV nicotine in squirrel monkeys.  
Mecamylamine, on the other hand, which has access to the brain, was able to attenuate 
these aversive effects of nicotine (Spealman 1983). However, it is unclear whether the 
α4β2* nAChRs are involved in these effects.  
 Recent findings from a genetic study using IV nicotine self-administration 
procedures in mice suggest that the aversive effects of nicotine maybe mediated 
through nAChRs containing the α5 subunit (Fowler et al. 2011). In this study, it was 
shown that both α5 KO mice and wild-type mice showed similar patterns of IV nicotine 
self-administration, since inverted U-shaped dose-response curves were obtained with 
both groups at doses of nicotine (0.03-1.0 mg/kg base formulation) that have been 
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shown to be reinforcing in other nicotine self-administration procedures in mice (see 
Shannon et al. 2007). However, α5 KO mice showed increased self-administration 
behavior at high unit doses of nicotine that are typically found on the descending (0.4-
0.6 mg/kg), but not the ascending limb of the inverted U-shaped dose-response curve 
of nicotine self-administration in wild-type mice (Fowler et al. 2011). While it was 
suggested that the nAChRs containing the α5 subunit may be involved in mediating the 
aversive effects of high doses of nicotine that are thought to limit rates of responding 
(e.g., Katz 1989; Rose and Corrigall 1997), pharmacological studies have yet to verify 
the role of the α5 subunit in self-administration behaviors due to limited availability of 
antagonists that are selective for nAChRs containing the α5 subunit  (see Daly 2005).  
Therefore, further investigation of the nAChR subtype(s) that mediate the aversive 
effects might be useful in understanding how the actions of nicotine on specific 
nAChRs control behavior. 
 
Choice Procedures 
 Choice procedures, an approach that has not been used previously to examine 
the aversive effects of nicotine may be useful in this regard. Choice procedures are 
operant procedures in which subjects can respond under one of two or more alternative 
schedules of reinforcement (typically available for responding on different manipulanda) 
that are presented concurrently. It has been suggested that an advantage of using 
choice procedures over procedures that use single operant situations is that it may 
provide a more sensitive measure of the aversive effects of non-drug (Azrin and Holz 
1966) and drug stimuli (Woolverton 2003; Negus 2005; Podlesnik 2010; Woolverton 
2012). For instance, Azrin and Holz (1966) reported that while decreases in rates of 
responding on a manipulandum that delivered food paired with electric shock was 
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inversely related to the intensity of the shock delivered in a single operant situation, the 
punishing effects of electric shock could be increased if pigeons were presented with a 
concurrently available manipulandum that delivered food without shock. That is, under 
a choice situation, the intensities of electric shock that were effective at suppressing 
rates of responding on the manipulandum that delivered food + electric shock were 
lower than in a single operant situation. The authors concluded that having an 
unpunished outcome as an alternative consequence enhanced the punishing effects of 
electric shock. Similar conclusions have also been made in a study examining the 
punishing effects of IV histamine on food-reinforced responding in rhesus monkeys 
(Woolverton 2003). In this study, rhesus monkeys were given the choice to respond on 
levers that delivered either food or food paired with an IV histamine injection. It was 
reported that monkeys decreased their responding on the lever that delivered food + 
histamine and reallocated responses to the lever that delivered food alone. Decreases 
in responding on the lever that delivered the food + histamine were dependent on the 
dose of histamine, with greater decreases observed with larger doses. While the study 
did not examine the effects of histamine in a non-choice situation, it was noted by the 
author that the doses of histamine that were found to be punishing in the study were 
approximately 10 fold lower than the ones used in published studies that used single 
operant situations (e.g., Goldberg 1980; Katz and Goldberg 1986).  
 Another possible advantage of using choice procedures is that it allows for a 
direct comparison between the relative strength of reinforcers and punishers by 
measuring the allocation of responding between manipulanda that deliver either a 
positive reinforcer paired with an aversive stimulus (i.e., punished consequence), or a 
positive reinforcer alone (i.e., unpunished consequence). Furthermore, examining the 
allocation of responding in choice situations can be used as a control to determine 
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whether decreases in positively reinforced behaviors is a result of a punishing effect or 
a direct effect (i.e., unconditioned rate suppressant effects) of the aversive stimulus 
being evaluated. For instance, if decreases in responding on a manipulandum that 
delivered a punished consequence also resulted in the reallocation of responses (i.e., 
increases in responding) on a different manipulandum that delivered a unpunished 
consequence, this demonstrates that decreases in responding were not a result of the 
direct suppressant effects of the punishing consequence (e.g., Woolverton 2003; Negus 
2005). Accordingly, choice procedures may provide a more sensitive measure of the 
aversive effects of nicotine than single operant situations, because a viable behavioral 
alternative is offered, which may offer advantages in terms of differentiating the 
punishing effects of a stimulus from its direct effects.  
 
Aims 
 The goal of these studies is to contribute to a general understanding of how 
operant behavior can be controlled by the aversive effects of IV drug administration. 
The specific goal of this research was to develop IV drug punishment procedures to 
study the aversive effect of nicotine, and to identify pharmacological and environmental 
variables that contribute to punishment by nicotine. The rationale for studying the 
punishing effects of nicotine is that it may provide insight on how the aversive effect of 
nicotine may contribute to the control of nicotine-taking behavior. 
 
Specific Aim 1 
 The first set of experiments (presented in Chapter 2) was designed to examine 
independent variables that may affect the punishing effects of IV drug administration in 
the rat. Using a choice procedure, rats were presented with two concurrently available 
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levers, in which responding on either lever resulted in the delivery of a sucrose pellet 
with or without an IV injection of histamine (a putative aversive stimulus).  This was used 
to examine whether manipulating the schedule of drug delivery or a response-
contingent drug history would affect the punishing effects of IV histamine. These 
studies were conducted to provide guidance in developing an operant procedure to 
study the aversive effects of IV nicotine and interpretation of data.  
 
Specific Aim 2 
 The second set of experiments (presented in Chapter 3) was designed to 
evaluate the aversive effects of IV nicotine by examining its punishing effects. In these 
experiments, rats were trained to respond on a lever that delivered sucrose pellets, and 
then the effects of response-independent and -dependent nicotine injections on 
sucrose-reinforced lever responding were examined. In addition, the dose of nicotine 
delivered per injection (0.01-0.18 mg/kg), the behavioral alternative to punished 
responding (i.e., choice vs. non-choice situation), and the delay between the response 
and the delivery of nicotine were manipulated to examine whether nicotine-induced 
decreases in rates of responding were due to a punishing effect or to a direct 
suppressant effect of the drug, and to determine whether nicotine is characteristically 
similar to other punishers. 
 
Specific Aim 3  
 The final set of experiments (presented in Chapter 4) was designed to elucidate 
the receptors involved in mediating the punishing effects of IV nicotine on sucrose-
reinforced lever responding in rats observed in Aim 2. Using the same punishment 
procedure developed in Aim 2, antagonist studies evaluating the effects of 
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mecamylamine and dihydro-beta-erythroidine pretreatments on the punishing effects of 
IV nicotine were conducted. 
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Chapter 2 
Effects of drug history and intertrial interval schedules 
on punished responding by IV histamine 
 
 
Introduction 
 The development of intravenous (IV) self-administration procedures to study a 
drug’s capacity to function as a positive reinforcer (i.e., a stimulus that increases the 
frequency of a behavior, which leads to the drug’s delivery) has been extremely useful 
in studying drugs of abuse (Johanson and Schuster 1981; Woolverton and Nader 1991; 
Jones and Comer 2013). However, the reinforcing effects of drugs alone may not 
describe all aspects of drug-taking behavior. For example, rates of responding tend to 
decrease with larger doses of drugs of abuse, as illustrated by the descending limb of 
the typical inverted U-shaped dose-response function of IV drug self-administration 
(Katz 1989). These decreases in behavior may be due in part to the aversive properties 
of drugs (Stolerman and D’Mello 1981; Katz 1989). Developing procedures to examine 
the aversive effects of drugs may be useful in understanding the general control of 
behavior by drugs of abuse.  
 One approach to studying the aversive effects of IV drugs is the development of 
punishment procedures, in which the ability of a drug to function as a punisher (i.e., a 
stimulus that decreases the frequency of behavior that leads to its delivery) is 
measured. Because punishment procedures measure a decrement in behavior, it can 
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be studied only if there is reasonable level of response behavior occurring. Such a level 
can be maintained with positive reinforcement, and therefore punishment studies must 
assess the effects of punishment in relation to some baseline of positively reinforced 
responding. Accordingly, studying the punishing effects of drugs is not without its 
difficulties. If an IV drug injection is delivered simultaneously with a positive reinforcer 
such as food, and if the behavior that was positively reinforced with food delivery 
decreases, then these decreases can be attributed to the effects of the drug (Goldberg 
1980; Katz and Goldberg 1986). However, controls are necessary to establish that the 
observed decreases in positively reinforced behavior are a result of punishment and not 
due to something else entirely, such as a direct suppressant effect of the drug upon 
reinforced responding. Additionally, since the punishing drug is studied in relation to its 
effects on the rates of a positively reinforced behavior, the nature of the reinforcer and 
its scheduled delivery must also be evaluated. For example, the magnitude (or amount) 
of a positive reinforcer has been reported to be a determinant of punishment: behaviors 
maintained by lower-magnitude reinforcers are more readily punished than higher-
magnitude reinforcers (Johanson 1977; Poling and Thompson 1977).  
 Choice procedures have been developed to study the punishing effects of IV 
drugs by examining the allocation of responding between two concurrently available 
manipulanda, which response-contingently deliver either the positive reinforcer with the 
IV drug injection, or the positive reinforcer alone (Woolverton 2003; Negus 2005; 
Podlesnik et al 2010). In these procedures, if responding is allocated toward the 
manipulandum that delivers the positive reinforcer alone, then this suggests that the 
drug is a punisher and does not have direct suppressant effects. Although choice 
procedures have been developed to evaluate the punishing effects of drugs (Goldberg 
1980; Katz and Goldberg 1986 Woolverton 2003; Negus 2005; Podlesnik et al. 2010), 
	  	   19	  
less is known about behavioral determinants of punishment as compared to 
reinforcement.  
  The purpose of the present study was to further evaluate the punishing effects 
of IV histamine injections (Woolverton 2003; Negus 2005; Podlesnik et al 2010) by using 
a choice procedure to examine whether schedule control of punisher delivery (through 
manipulation of intertrial interval length), or subjects’ drug histories affect punishment of 
sucrose-reinforced lever pressing in rats. In self-administration studies examining the 
reinforcing effects of IV cocaine, altering time-out (i.e., the time following reinforcement 
during which response manipulanda are available but responding has no scheduled 
consequences) has been shown to affect rates of responding (Winger 1993; Woolverton 
1995; Rowlett et al. 1996; Nader and Morgan 2001; Martelle et al. 2008). However, it 
remains unclear whether varying the amount of programmed time between response-
dependent delivery of a punisher can affect punishment. Furthermore, researchers have 
noted that a drug’s ability to act as a reinforcer and maintain later drug self-
administration in a subject can be influenced by a previous history with that drug (see 
Young et al. 1981). For instance, rhesus monkeys increase their response rates for 
smaller doses of cocaine that were not initially self-administered if they had established 
a self-administration history with a larger dose of cocaine (Goldberg 1973; Downs and 
Woods 1974). Although a drug history can influence the effects of positively reinforcing 
compounds, it is not known what kind of drug history might affect the punishing effects 
of drugs. The ability of drug histories to subsequently alter a drug’s ability to punish 
positively reinforced behaviors has not been investigated and may be important in 
predicting behavioral effects.  
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Methods   
 All experimental procedures were approved by the University of Michigan 
Committee on the Use and Care of Animals and performed in accordance with the 
Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the 
National Institutes of Health. 
Subjects 
  Male Sprague-Dawley rats (300-375 g) were obtained from Harlan (Indianapolis, 
IN) and housed in a temperature- (21-23 °C) and humidity-controlled environment on a 
12-h dark/light cycle, with lights on at 7:00 A.M. Rats were housed three per cage 
during non-drug behavioral training procedures, and then individually housed after 
surgery was completed. Except during experimental sessions, rats had free access to 
tap water and were on food-restricted diets of Purina rodent chow that maintained at 
least 80% of their pre-restriction body weights. All experiments were conducted 5-7 
days/week between 9:00 A.M and 5:00 P.M.  
Apparatus 
 Med Associates (St. Albans, VT) operant conditioning chambers and manipulanda 
were used for all experiments. Each operant conditioning chamber was approximately 
30 cm long, 24 cm wide, and 21 cm high, and each chamber was contained in a sound-
attenuating cubicle. The front panel of each operant conditioning chamber was 
equipped with two retractable levers, 6.8 cm above the grid floor, and 1.3 cm from the 
side walls, with an array of red, yellow, and green light-emitting diodes (LEDs) above 
each lever. A 2.8V white incandescent house light was located at the top center of the 
rear panel. Located between the two levers was a magazine in which a 45 mg sucrose 
pellet (Bio-Serv, Frenchtown, NJ) could be delivered. IV drug injections were delivered 
by a motorized syringe driver (PHM-107; Med Associates) through Tygon tubing (S-54-
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HL, Norton Performance Plastics, Akron, OH) connected to a swivel that was held in 
place by a counterbalanced arm. Syringe drivers were located outside the sound-
attenuating chamber. Injection durations were determined by the weight of each rat 
divided by the drug delivery pump flow rate (0.072 ml/s). Data were collected with Med 
Associates software.  
Non-Drug Behavioral Training Procedures 
  Rats first received one 60 min session in which they were trained to eat sucrose 
pellets from the magazine located inside the operant chamber. No levers were available 
during this time, and sucrose pellets were delivered on a random-time 60 s schedule. 
Rats then received two 60 min daily sessions in which they were trained to respond on 
both levers. In these sessions, each lever was presented individually in alternating 
sequence. Rats were given 8 s to press the lever each time it was presented. If a 
response was made (or no response was made after 8 s), then a sucrose pellet was 
delivered, the lever retracted, and the LEDs were turned off until the lever was 
presented again. Intertrial intervals (ITI), which are timed intervals between trials when 
no lever is available and, therefore, no responses could be made, were each 60 s long. 
Each ITI began when the lever retracted.  
 Behavioral training finished with a single 90 min “choice” training session. In this 
session, a response made on either lever, delivered a sucrose pellet. The choice 
training session began with two “lever trials” followed by a series of “choice trials.” 
Lever trials were initiated when one of the two levers was randomly extended into the 
chamber with the three LEDs above that lever turned on. Rats were given 60 s to press 
the lever after it was presented. If a response was made, sucrose was delivered, the 
lever retracted, and the LEDs were turned off. If no response was made within the 60 s, 
then the lever retracted, the LEDs were turned off, and no sucrose was delivered. Lever 
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trials were presented to allow rats to sample the consequences of responding on each 
lever before choice trials began. After the two lever trials were presented, choice trials 
were initiated with the simultaneous extension of both levers and the LEDs above both 
of the levers turned on. Under a concurrent (and mutually exclusive) fixed ratio 1- fixed 
ratio 1 (FR1-FR1) schedule, rats were presented with the opportunity to respond on one 
of the two available levers. If a response was made on either lever, sucrose was 
delivered, both of the levers retracted, and all of the LEDs were turned off. If no 
response occurred within 60 s, both levers retracted, all of the LEDs were turned off 
and no sucrose was delivered. Each ITI was 120 s long and began when the lever(s) 
retracted.  
Surgery 
 After non-drug behavioral training was completed, rats were surgically implanted 
with chronic indwelling IV catheters. Rats were anesthetized with ketamine (100 mg/kg; 
IP) and xylazine (10 mg/kg; IP) before a longitudinal incision was made to expose the 
femoral vein into which a catheter constructed from Micro-Renathane (Braintree 
Scientific, Inc., Braintree, MA) was inserted. The catheter was passed subcutaneously 
to an incision made between the scapulae and was then connected to a metal cannula 
that exited the skin. Catheters were flushed daily with 0.5 ml (100 U/ml) of heparinized 
saline to maintain patency. Rats were allowed at least 5 days to recover from surgery; 
during this time rats had unrestricted access to food and water.  
Testing Procedures 
 All testing procedures began after rats recovered from surgery. For each 
experiment there were two phases (I and II) that were conducted sequentially (see Table 
2.1 for schematic overview of experiments). Each phase consisted of 10 daily 
experimental sessions, and the choice procedure used in all sessions was the same 
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one as described for the choice training session with the exception of the 
consequences of responding on the levers and length of ITIs.  
 Experiment 1. Evaluating the punishing effects of histamine on lever 
responding, which delivered either sucrose+histamine, or sucrose alone, under 
different ITI schedules (5, 60, or 120 s). In phase I, the lever on which a rat made 
fewer responses during choice training was designated lever 1, and responding on this 
lever resulted in the delivery of a sucrose pellet. The lever on which a rat made more 
responses during choice training was designated lever 2, and the consequence of 
responding on lever 2 was the delivery of a sucrose pellet paired with an IV injection of 
1.0 mg/kg histamine (sucrose+histamine). In phase II, the consequences of responding 
on the levers were reversed, such that responding on lever 1 now delivered 
sucrose+histamine, and responding on lever 2 now delivered a sucrose pellet alone. 
The consequences of responding on the levers were reversed to determine whether a 
reinforcer preference  (i.e., responding controlled by consequences) or a position 
preference (i.e., responding controlled by location of the physical lever) was controlling 
response behavior. Three separate groups were used to evaluate lever responding with 
programmed ITI times of 5, 60, or 120 s (n=6 per group). For each 90 min session, the 
maximum number of choice trials that could be completed was 48 with a 5 or 60 s ITI 
and 43 with a 120 s ITI. 
 Experiment 2. Evaluating the punishing effects of histamine on lever 
responding, which delivered either sucrose+histamine, or sucrose alone, in rats 
with different drug histories. In phase I, the lever on which a rat made fewer 
responses during choice training was designated lever 1, and the assigned 
consequence of responding on this lever was the delivery of a sucrose pellet. The lever 
on which a rat made more responses during choice training was designated lever 2, 
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and consequence of responding on lever 2 was the delivery of an IV injection of saline 
or histamine (0.3 or 1.0 mg/kg per injection). In phase II, the consequences of the levers 
were changed, such that responding on lever 1 now delivered a sucrose pellet paired 
with an IV injection of 1.0 mg/kg histamine, and responding on lever 2 now delivered 
sucrose alone. Therefore in phase II, all rats were presented with the choice to respond 
on lever 1, which delivered sucrose+histamine, or lever 2, which delivered sucrose 
alone. Three separate groups were used to evaluate lever responding in rats with 
different drug histories (saline, 0.3, or 1.0 mg/kg histamine history) (n=6 per group). For 
each 90 min session, the maximum number of choice trials that could be completed 
was 43 with each ITI 120 s long.  
Drugs 
 Histamine dihydrochloride was obtained from Sigma-Aldrich (St.Louis, MO) and 
dissolved in 0.9% saline solution. Histamine doses were calculated using the salt form 
of the drug and chosen according to reported behavioral activity in rats (Podlesnik et al. 
2010).  
Data Analyses 
 For all experiments, the dependent variable measured in each session was the 
number of responses made on each lever. In general, ANOVAs were used to determine 
changes in lever responding across sessions and differences in lever responding 
among groups. Significant ANOVAs were followed by Bonferroni post hoc tests. All 
statistical tests used an alpha of 0.05, two-tailed. Analyses were performed using Prism 
6.0 (GraphPad Software, La Jolla, CA, USA).  
 Experiment 1. To examine the punishing effects of histamine under each ITI 
schedule, two-way repeated measures ANOVAs with the within-subjects factors of 
lever and sessions were used to analyze lever responding in each phase. To determine 
	  	   25	  
if there was a difference in punishment among groups in each phase, punished-choice 
responding defined as [(number of ratios completed on the sucrose+histamine lever 
during choice trials ÷ total number of ratios completed for all choice trials)×100] were 
analyzed using two-way repeated measures ANOVAs with length of ITI (5 s vs. 60 s vs. 
120 s), and sessions as the two factors. Punished-choice responding was used for 
analyses because of differences in the maximum number of responses that could have 
been made among the different ITI schedules.  
 Experiment 2. In each group, to determine if pairing a 1.0 mg/kg histamine 
injection with sucrose delivery in phase II punished responding on lever 1, a one-way 
repeated measures ANOVA was used to analyze responses made on lever 1 across 
sessions 10-20. One-way repeated measures ANOVAs were also used to determine if 
changing the consequence of responding on lever 2 in phase II affected lever 
responding on lever 2. To determine if drug histories affected punishment, responses 
made on lever 1 were averaged across sessions in phase I, and phase II, and the mean 
responses made in each phase by each group was compared using a two-way ANOVA 
with the within-subjects factor of consequence of lever 1 in each phase (sucrose vs. 
sucrose+histamine) and the between-subjects factor of drug history (saline vs. 0.3 vs. 
1.0 mg/kg histamine).  
 
Results  
 Effects of ITI schedule on the punishing effects of histamine on lever 
responding, which delivered either sucrose+histamine (1.0 mg/kg per injection), or 
sucrose alone. In general, all groups’ responding on lever 1 (sucrose) increased and 
responding on lever 2 (sucrose+histamine) decreased across sessions in phase I. When 
the consequences of the levers were reversed in phase II, responding on lever 1 
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(sucrose+histamine) decreased as responding on lever 2 (sucrose) increased across 
sessions (Fig. 2.1a-c). In the 5 s ITI group (Fig. 2.1a), differences in responding between 
levers in phase I were affected by sessions [main effect of lever: F (1,10)=20.68, 
p=0.001; session x lever interaction: F (9,90)=10.51, p<0.0001]. Rats made more 
responses on lever 1 than on lever 2 in each session from 4 to 10. Additionally, the 
average number of total lever responses made in each session differed across sessions 
in phase I [main effect of session: F (9,90)=5.93, p=<0.0001], such that the number of 
total responses made in each session from 6 to 10 was greater than in session 1. In 
phase II, there was no significant difference in responding between levers, however 
responding on lever 2 differed across sessions [main effect of session: F (9,90)=4.12, 
p=0.0002; session x lever interaction: F (9,90)=5.56, p<0.0001], such that responses 
were significantly greater in session 19 and 20 compared to session 11.  
 In the 60 s ITI group (Fig. 2.1b), differences in responding between levers in 
phase I were affected by sessions [main effect of lever: F (1,10)=25.47, p=0.005; 
session x lever interaction: F (9,90)=15.86, p<0.0001]. Rats made more responses on 
lever 1 than on lever 2 in each session from 4 to 10. When the consequences of the 
levers were reversed in phase II, responding on lever 1 decreased while responding on 
lever 2 increased [session x lever interaction: F (9,90)=2.78, p=0.006], however there 
was no significant difference in lever responding between levers or changes in total 
number of responses across sessions. 
 In the 120 s ITI group (Fig. 2.1c), differences in responding among levers in 
phase I were different [main effect of lever: F (1,10)=17.20, p=0.002] with more 
responses made on lever 1 than lever 2.  However, differences in lever responding were 
not affected by sessions. When the consequences of the levers were reversed in phase 
II of the experiment, responding on lever 1 decreased while responding on lever 2 
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increased [session x lever interaction: F (9,90)=7.94, p<0.0001], however there was not 
significant difference in responding between levers across sessions. 
 Punished-choice responding (i.e., percent of total responding allocated on the 
lever that delivered sucrose+histamine) was not different among ITI groups (Fig 2a and 
b). However, the punished-choice responding differed across sessions in phase I [main 
effect of session: F (9,126)=9.07, p<0.0001] (Fig. 2.2c) and across sessions in phase II 
[main effect of session: F (9,126)=8.02, p<0.0001] (Fig. 2.2d). In phase I, punished-
choice responding in each session from 6 to 10 decreased as compared to session 1 
and decreases were also observed in each session from 18 to 20 compared to session 
11.  
 Effects of drug history on responding on levers, which delivered either 
sucrose+histamine (1.0 mg/kg per injection), or sucrose alone. In phase I, each 
group readily acquired responding on lever 1 (sucrose), and made little or no responses 
on lever 2 (injection). By session 10 each group made all of their responses on lever 1 
(sucrose) (Fig. 2.3a-c). In the initial sessions, in which rats did make responses on lever 
2 (injection), the 1.0 mg/kg histamine history group received, on average, the greatest 
total daily histamine intake among the groups, such that this group received 
approximately 4 times more histamine (Table 2.2). For instance, in session 1, the 1.0 
mg/kg histamine and 0.3 mg/kg groups received 11.2±1.7 and 2.8±0.8 mg/kg histamine 
respectively, whereas the saline history group received no histamine, because the only 
injections the rats could receive was saline. 
 When the consequences of responding on the levers were changed in phase II of 
the experiment, responding on lever 1 (sucrose+histamine) generally decreased across 
sessions in each group, with some increase in responding on lever 2 (sucrose) (Fig. 
2.3a-c). In the saline history group, responding differed across sessions on lever 1 [main 
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effect of session: F (10, 50)=13.20, p<0.0001] and lever 2 [main effect of session: F (10, 
50)=3.61, p=0.001] (Fig. 2.3a). Rats in the saline history group made fewer responses 
on lever 1 in each session from 11 to 20 as compared to session 10 and made more 
responses on lever 2 in each session from 18-20 compared to session 10.  
 In the 0.3 mg/kg histamine history group, responding differed across sessions on 
lever 1 [main effect of session: F (10, 40)=5.16, p<0.0001] and lever 2 [main effect of 
session: F (10, 40)=2.99, p=0.006] (Fig. 2.3b). Rats in the 0.3 mg/kg histamine history 
group made fewer responses on lever 1 in each session from 11 to 20 compared to 
session 10, and increased responding on lever 2 in each session from 18 to 20 
compared to session 10.  
 In the 1.0 mg/kg histamine history group, responding differed across sessions on 
lever 1 [main effect of session: F (10, 50)=40.06, p=0.0004] and lever 2 [main effect of 
session: F (10, 50)=2.49, p=0.01] (Fig. 2.3c). Rats in the 1.0 mg/kg histamine history 
group made fewer responses on lever 1 in session in 11, and each session from 15 to 
20 compared to session 10. However, while responding on lever 2 differed across 
sessions, none of the individual sessions significantly differed from responding in 
session 10.  
  Between-subject comparisons revealed that the punishing effects of 1.0 mg/kg 
histamine injections in phase II were dependent on the unit dose of histamine injections 
available in phase I (Fig. 2.4). Group-averaged responding on lever 1 decreased in 
phase II [main effect of consequence: F (1, 28)=51.75, p<0.0001], and the decreases 
were dependent on the unit dose of histamine available in phase I, in which the greatest 
decrease was observed in the saline history group, followed by the 0.3 mg/kg histamine 
history group.  Averaged responding on lever 1 by the 1.0 mg/kg histamine did not 
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significantly decrease in phase II, with rats making significantly more responses on lever 
1 compared to the saline history group.   
 
Discussion 
 The purpose of the present study was to examine whether manipulation of ITI 
length and/or drug history affected the punishing effects of IV histamine injections on 
sucrose-reinforced lever responding in rats. In general, sucrose served as a reinforcer 
of lever responding, whereas IV histamine injections served as a punisher of sucrose-
reinforced lever responding. When rats were presented with levers that delivered either 
sucrose or sucrose+histamine, rats generally decreased their responding on the 
sucrose+histamine lever while increasing their responding on the sucrose-only lever. 
These findings are consistent with published studies in which IV histamine injections 
punished both food- (Woolverton 2003; Podlesnik et al 2010) and cocaine-reinforced 
behaviors (Negus 2005; Woolverton et al. 2012), while increasing “unpunished” 
responding (i.e., the positively reinforced behavioral alternative) in choice situations. 
Although histamine injection served as a punisher of sucrose-reinforced lever 
responding under the present conditions studied, attenuation of the punishing effects of 
histamine was observed in rats that had a drug history involving response-contingent 
histamine when compared to rats with no drug history. In contrast, the punishing 
effects of histamine may have been increased with a shorter ITI (e.g., 5 s).  
Effects of ITI on punishment by histamine  
 When rats were presented with the choice to respond on levers that delivered 
either sucrose only or sucrose+histamine, punished-choice responding decreased 
across sessions in both phase I and phase II (after lever consequences were reversed). 
This suggests that responding was controlled by consequences, and not position 
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preference. The decreases in punished-choice responding indicates that pairing 
histamine with sucrose delivery resulted in rats allocating fewer of their total responses 
on the sucrose+histamine lever, and/or increased their responses on the sucrose lever 
across sessions. These changes across sessions demonstrate that histamine served as 
a punisher of sucrose-reinforced responding, and in some instances, punishment 
coincided with rats increasing their responding on the alternative lever, which delivered 
sucrose alone.    
 Although there was no difference in punished-choice responding among the 
different ITI groups, the total number of responses made within each session differed. 
In the 5 s ITI group, the total number of responses made in each session differed across 
sessions in both phase I and phase II, such that the total number of responses made in 
the initial sessions of both phases was lower (because of missed trials) than responses 
made in sessions at the end of each phase. Rats in the 60 and 120 s ITI groups did not 
significantly miss any trials, and the total number of responses made in each session 
did not differ across sessions. These findings suggest that a 5 s ITI may have resulted 
in some direct suppressant effects on behavior.  
 However, the reduction in responses made on the sucrose+histamine lever was 
more complete in the 5 s ITI group, such that responding was reduced to zero in phase 
I, and remained low in phase II compared to the 60 and 120 s ITI groups. Therefore, 
while a shorter ITI may have resulted in some direct suppressant effects, it may have 
also increased the punishing effects of histamine. For instance, responding on the 
sucrose lever by rats in the 5 s ITI group remained completely suppressed for several 
sessions in phase II despite the histamine consequence being removed. This may have 
occurred because the punishing effects established in phase I were long-lasting. Other 
studies have noted that the effects of punished behavior may remain even after the 
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punishment contingency has been removed (see Azrin and Holz 1966).  
 One explanation as to how a shorter ITI could have increased the punishing 
effects of histamine is that rats in the 5 s ITI can be punished with greater frequency 
compared to the 60 or 120 s ITI. It has been reported that punishment schedules that 
are analogous to a continuous schedule of reinforcement (i.e., FR1 schedule of 
reinforcement without scheduled timeouts) result in greater punishment of behavior 
(Azrin et al. 1963). In rhesus monkeys, Negus (2005) found that punishment of cocaine-
reinforced behavior by intravenous histamine injections was directly related to the 
“probability” (or schedule) of histamine being delivered with cocaine. In this study, 
response-contingent histamine significantly decreased cocaine-reinforced responding 
when the probability of histamine delivery with cocaine was 100% (an injection followed 
every reinforced response). In contrast, when the probability of delivery was decreased 
to 33% (an injection followed every third reinforced response), responding was similar 
to that of subjects that had 0% probability of receiving histamine injections. These 
findings suggest that the frequency of punisher delivery is important in punishment, just 
as it is with reinforcement (see Spealman and Goldberg 1978). Therefore, decreasing 
the length of ITI in the present study may have actually resulted in greater punishment 
(albeit with the possibility of some direct suppressant effect), which is not apparent in 
the analysis of punished-choice responding. 
Effect of drug histories on punishment by histamine  
 When the consequence of responding on lever 1 was changed from the delivery 
of sucrose alone to the delivery of sucrose paired with an injection of histamine (1.0 
mg/kg), responding on lever 1 decreased. However, the punishing effect of histamine 
on sucrose-reinforced lever responding was attenuated in groups with a history of 
histamine compared to groups that had a saline history (i.e., no drug history). The 
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extent to which histamine punished sucrose-reinforced responding on lever 1 was 
related to the unit dose of histamine previously delivered as a consequence of 
responding on lever 2. Accordingly, attenuation of punishment was greater in the 1.0 
mg/kg histamine history group compared to the saline history group.  
 It is possible that a drug history of response-contingent IV histamine may have 
resulted in tolerance to the punishing effects of histamine, such that rats that received 
histamine in phase I were less sensitive to the punishing effects of 1.0 mg/kg histamine 
in phase II. Tolerance to the punishing effects of electric shock, for instance, has been 
reported to occur with repeated exposure in rhesus monkeys (Bergman and Johanson 
1981). However, development of tolerance to histamine cannot account for the fact that 
the punishing effects of histamine persist across sessions in phase II (in which rats are 
repeatedly exposed to histamine). Alternatively, a history of IV histamine or saline self-
administration established on lever 2 could have attenuated the punishing effects of 
histamine by affecting reallocation of punished responding in phase II. For instance, 
although the consequence of the levers were changed in phase II (so that responding 
on lever 2 delivered sucrose alone, and responding on lever 1 delivered sucrose paired 
with an injection of 1.0 mg/kg histamine), responding on lever 2 was low in all groups, 
with responding completely suppressed for several sessions in the 1.0 mg/kg histamine 
history group. The saline history group, while not statistically significant, made, on 
average, 10.2±5.5 responses on the lever 2 (sucrose), which was more than the 
responses made by 0.3 or 1.0 histamine history group, which averaged 9.3±5.8 and 
3.6±2.0 respectively. The low number of responses made on lever 2, and differences in 
responding among the groups may reflect a long-lasting effect of the self-administration 
history established on the respective lever when it had previously delivered an injection 
of saline or histamine (0.3 or 1.0 mg/kg). While it is possible that histamine had direct 
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suppressant effects that prevented reallocation of behavior, the 1.0 mg/kg histamine 
history group received more injections than either the saline or 0.3 mg/kg histamine 
history group, and yet the total amount of responses made in each session did not 
differ among groups.  
 Other studies using choice procedures have demonstrated that providing an 
equivalent reinforcer that is unpunished as an alternative response consequence may 
facilitate a more sensitive measurement of punishment, such that the intensity of 
electric shock (Azrin and Holz 1966) or the dose of IV histamine (Woolverton 2003) 
needed to punish behavior is less than when no alternative unpunished reinforcer is 
available. This suggests that the saline history group was not more sensitive to the 
punishing effects of 1.0 mg/kg histamine (i.e., less tolerant of histamine), but, rather, 
that the measurement of punishment was affected by whether rats reallocated 
punished responding. A future study in which no alternative unpunished reinforcer 
consequence is provided in phase II may help determine whether the attenuation of the 
punishing effect of histamine was a result of drug history that affected reallocation of 
behavior, or a tolerance that developed to histamine.  
Conclusions 
 The results of this study demonstrate that while histamine functioned to punish 
sucrose-reinforced lever responding, drug history and schedule of punisher delivery 
may be important variables to consider when examining the punishing effects of IV 
drugs. Therefore, examining conditions under which drugs are studied may have 
practical implications in understanding the general effects of drugs. The findings in this 
study agree with the general conception that the behavioral effects of drugs can be 
altered by a number of conditions including the ongoing rate of responding, behavioral 
and drug history, and the current behavioral conditions (see Morse and Kelleher 1977).  
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Table 2.1 Consequences of responding on lever 1 and lever 2 in phases I and phase II 
for each histamine punishment experiment conducted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
 Consequences of responding on levers 
 Phase I: Sessions 1-10 
 
Phase II: Sessions 11-20 
 
 Lever 1 Lever 2 Lever 1 Lever 2 
Experiment 1 
Evaluating the punishing effects 
of intravenous histamine 
injections under different ITI 
schedules (5 vs. 60 vs. 120 s) 
 
sucrose sucrose+ 
histamine  
 
(1.0 mg/kg 
histamine  per 
injection) 
sucrose+ 
histamine  
 
(1.0 mg/kg 
histamine  per 
injection) 
sucrose 
Experiment 2 
Evaluating the punishing effects 
of intravenous histamine in rats 
with drug histories (saline vs. 
0.3 vs. 1.0 mg/kg histamine 
history) 
 
sucrose saline injection  
or  
0.3 mg/kg/inj 
histamine  
or  
1.0 mg/kg/inj 
histamine  
 
sucrose+ 
histamine  
 
(1.0 mg/kg 
histamine  per 
injection) 
sucrose 
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Table 2.2 Values for total injections delivered and total histamine intake (mg/kg) across 
sessions 1-10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
 Saline injection Histamine (0.3 mg/kg/inj) 
 
Histamine (1.0 mg/kg/inj) 
 
Total injections Total intake 
mg/kg 
Total injections Total intake 
mg/kg 
Total injections Total intake 
mg/kg 
Session 1 
Session 2 
Session 3 
Session 4 
Session 5 
Session 6 
Session 7 
Session 8 
Session 9 
Session 
10 
14.8±4.0 
3.6±0.9 
0.8±0.5 
1.6±0.9 
0.6±0.4 
0 
0 
0 
0.8±0.8 
0.2±0.2 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
n/a 
9.6±2.7 
3.2±1.3 
2.2±1.2 
.06±0.4 
.04±0.4 
00 
00 
0.2±0.2 
0 
0 
2.8±0.8 
0.9±0.3 
0.6±0.3 
0.01±0.01 
0.01±0.01 
0 
0 
0.06±0.06 
0 
0 
11.2±1.7 
4.2±1.8 
0.8±0.3 
0.6±0.4 
0 
0.4±0.4 
0 
0 
0.4±0.2 
0.2±0.2 
11.2±1.7 
4.2±1.8 
0.8±0.3 
0.6±0.4 
0 
0.4±0.4 
0 
0 
0.4±0.2 
0.2±0.2 
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Figure 2.1 
                                  
Figure 2.1 Responding on levers that delivered either sucrose+histamine (1.0 
mg/kg) or sucrose under different ITI schedules. Each graph displays data from 
individual groups that differ by their ITI schedule: (a) 5 s ITI, (b) 60 s ITI, and (c) 120 s ITI 
(n=6 per group). Closed and open symbols represent the mean (±SEM) responses 
made on levers 1 and 2 respectively. Legends next to the symbols listed in the table 
indicate the consequences of responding on lever 1 and lever 2 across sessions 1-20. 
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Figure 2.2  
   
Figure 2.2 Punished-choice responding under different ITI schedules. Open and 
closed symbols represent the mean (±SEM) percent of punished-choice responding by 
individual groups (a and b) (n=6 per group) and of all groups respectively (c and d). *, 
p<. 05, **, p<0. 01***, p<0. 001, ****, p<0. 0001. Significant decrease in punished-choice 
responding across sessions compared to the first session within each phase. 
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Figure 2.3  
 
 
 
Figure 2.3 Effects of drug history on lever responding that delivered either 
sucrose+histamine (1.0 mg/kg) or sucrose. Each graph displays data from individual 
groups that differ by their drug history, which corresponds to the dose of histamine or 
saline “injection” available on lever 2 in phase I: (a) saline history, (b) 0.3 mg/kg 
histamine history and (c) 1.0 mg/kg histamine history (n=6 per group). Closed and open 
symbols represent the mean (±SEM) responses made on levers 1 and 2 respectively. 
Legends next to the symbols listed in the table indicate the consequences of 
responding on lever 1 and lever 2 across sessions 10-20. *, p<. 05, **, p<0. 01***, p<0. 
001, ****, p<0. 0001. Significant difference in responding on lever 1 compared to 
session 10. +, p<. 05, ++, p<0. 01. Significant difference in responding on lever 2 
compared to session 10.  
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Figure 2.4 
 
        
 
Figure 2.4. Responding on lever 1 in phase I and phase II. Symbols represent data 
from individual groups that differ in their drug history as indicated by legends to the 
right of the symbols (n=6 per group). Responses made on lever 1 in phase I (sucrose 
consequence) and phase II (sucrose+1.0 mg/kg histamine consequence) by each group 
are presented as the mean (±SEM). **, p<0. 01***, p<0. 001. Significant difference in 
responding on lever 1 in phase I compared to phase II. #, p<0. 05. Significant difference 
in responding on lever 1 in phase II between saline history and 1.0 mg/kg histamine 
history group.  
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Chapter 3 
Punishing effects of intravenous nicotine in rats 
 
 
Introduction 
 Intravenous (IV) nicotine self-administration studies have demonstrated that 
nicotine can function as a positive reinforcer (i.e., a stimulus that increases the 
frequency of behavior that leads to its delivery) in rodents (e.g., Corrigall and Coen 
1989; Donny et al. 1995; Watkins et al. 1999), non-human primates (e.g., Goldberg et al. 
1981; Le Foll et al. 2007), and humans (e.g., Harvey et al. 2004; Sofuoglu et al. 2008). 
However, compared to other drugs of abuse, establishing the reinforcing effects of 
nicotine in controlled studies remains difficult (see Le Foll and Goldberg 2009). For 
instance, it has been reported that control of experimental parameters such as drug 
infusion duration (Wakasa et al. 1995), non-drug paired stimuli (Goldberg et al. 1981; 
Chaudhri et al. 2006), and schedule control of nicotine availability (Henningfield and 
Goldberg 1983) are all important in establishing and maintaining self-administration 
behavior. Therefore, while self-administration procedures have been developed to 
demonstrate the reinforcing effects of IV nicotine, very specific conditions are often 
required to obtain such effects.  
 These difficulties in demonstrating the reinforcing effect of nicotine may be due 
in part to the aversive properties of nicotine (Benowitz 1990). It is hypothesized that 
higher reinforcing doses of nicotine found on the descending limb of the inverted U-
shaped dose-response function of nicotine self-administration may also
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have aversive properties that limit rates of responding and total drug intake (e.g., Katz 
1989; Rose and Corrigall 1997). However, it is unclear whether decreases in rates of 
self-administration are a result of direct suppression of behavior and/or if they are due 
to the aversive effects of nicotine. Early investigations of IV nicotine self-administration 
noted that unit doses of nicotine that were reinforcing in squirrel monkeys (Goldberg et 
al. 1981) could also function to punish food-reinforced lever responding (Goldberg and 
Spealman 1982; 1983), and maintain lever responding to avoid its scheduled injection 
(Spealman 1983). Similarly, it has been reported that humans will also maintain 
responding to avoid IV injections of nicotine (Henningfield and Goldberg 1983). These 
findings indicate that the behavioral effects of nicotine can be divergent. However, 
investigation of the aversive effects of nicotine beyond these early studies described 
has been limited. A better understanding of the aversive effects of nicotine may be 
useful in understanding control of behavior by nicotine in more general circumstances. 
  The purpose of this study is to extend the evaluation of the aversive effects of IV 
nicotine injections by determining variables that may influence the punishing effects of 
IV nicotine on sucrose-reinforced responding in the rat. Using punishment procedures, 
dose of nicotine delivered per injection, the behavioral alternative to punished 
responding (i.e., reinforced vs. non-reinforced), and the delay of nicotine delivery were 
manipulated to determine whether punishment by nicotine is characteristically similar to 
other functional punishers. Additionally, the effects of response-independent nicotine 
were examined to determine what the rate-limiting cumulative dose of nicotine is. These 
experimental parameters were chosen because they have been shown to affect 
suppression of response behavior by punishers such as electric shock (Azrin and Holz 
1966; Grove and Schuster 1974) and IV histamine (Woolverton 2003; Woolverton et al. 
2012).  
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Methods   
 All experimental procedures were approved by the University of Michigan 
Committee on the Use and Care of Animals and performed in accordance with the 
Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the 
National Institutes of Health. 
Subjects 
 Male Sprague-Dawley rats (300-375 g) were obtained from Harlan (Indianapolis, 
IN) and housed in a temperature- (21-23 °C) and humidity-controlled environment on a 
12-h dark/light cycle, with lights on at 7:00 A.M. Rats were housed three per cage 
during non-drug behavioral training procedures, and then individually housed after 
surgery was completed. Except during experimental sessions, rats had free access to 
tap water and were on food-restricted diets of Purina rodent chow that maintained at 
least 80% of their pre-restriction body weights. All experiments were conducted 5-7 
days/week between 9:00 A.M and 5:00 P.M.  
Apparatus  
 Med Associates (St. Albans, VT) operant conditioning chambers and manipulanda 
were used for all experiments. Each operant conditioning chamber was approximately 
30 cm long, 24 cm wide, and 21 cm high, and each chamber was contained in a sound-
attenuating cubicle. The front panel of each operant conditioning chamber was 
equipped with two retractable levers, 6.8 cm above the grid floor, and 1.3 cm from the 
side walls, with an array of red, yellow, and green light-emitting diodes (LEDs) above 
each lever. A 2.8V white incandescent house light was located at the top center of the 
rear panel. Located between the two levers was a magazine in which a 45 mg sucrose 
pellet (Bio-Serv, Frenchtown, NJ) could be delivered. IV drug injections were delivered 
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by a motorized syringe driver (PHM-107; Med Associates) through Tygon tubing (S-54-
HL, Norton Performance Plastics, Akron, OH) connected to a swivel that was held in 
place by a counterbalanced arm. Syringe drivers were located outside the sound-
attenuating chamber. Injection durations were determined by the weight of each rat 
divided by the drug delivery pump flow rate (0.072 ml/s). Data were collected with Med 
Associates software.  
Non-Drug Behavioral Training Procedures and Surgery 
 Rats first received one 60 min session in which they were trained to eat sucrose 
pellets from the magazine located inside the operant chamber. No levers were available 
during this time, and sucrose pellets were delivered on a random-time 60 s schedule. 
Rats then received two 60 min daily sessions in which they were trained to respond on 
both levers. In these sessions, each lever was presented individually in alternating 
sequence. Rats were given 8 s to press the lever each time it was presented. If a 
response was made (or no response was made after 8 s), then a sucrose pellet was 
delivered, the lever retracted, and the LEDs were turned off until the lever was 
presented again. Intertrial intervals (ITI), which are timed intervals between trials when 
no lever is available and, therefore, no responses could be made, were each 60 s long. 
Each ITI began when the lever retracted.  
 Behavioral training finished with a single 90 min “choice” training session. In this 
session, a response made on either lever, delivered a sucrose pellet. The choice 
training session began with two “lever trials” followed by a series of “choice trials.” 
Lever trials were initiated when one of the two levers was randomly extended into the 
chamber with the three LEDs above that lever turned on. Rats were given 60 s to press 
the lever after it was presented. If a response was made, sucrose was delivered, the 
lever retracted, and the LEDs were turned off. If no response was made within the 60 s, 
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then the lever retracted, the LEDs were turned off, and no sucrose was delivered. Lever 
trials were presented to allow rats to sample the consequences of responding on each 
lever before choice trials began. After the two lever trials were presented, choice trials 
were initiated with the simultaneous extension of both levers and the LEDs above both 
of the levers turned on. Under a concurrent fixed ratio 1- fixed ratio 1 (FR1-FR1) 
schedule, rats were presented with the opportunity to respond on one of the two 
available levers. If a response was made on either lever, sucrose was delivered, both of 
the levers retracted, all of the LEDs were turned off, and no sucrose was delivered. If no 
response occurred within 60 s, both levers retracted and all of the LEDs were turned 
off. Each ITI was 120 s long and began when the lever(s) retracted.  
 After non-drug behavioral training was completed, rats were surgically implanted 
with chronic indwelling IV catheters. Rats were anesthetized with ketamine (100 mg/kg; 
IP) and xylazine (10 mg/kg; IP) before a longitudinal incision was made to expose the 
femoral vein into which a catheter constructed from Micro-Renathane (Braintree 
Scientific, Inc., Braintree, MA) was inserted. The catheter was passed subcutaneously 
to an incision made between the scapulae and was then connected to a metal cannula 
that exited the skin. Catheters were flushed daily with 0.5 ml (100 U/ml) of heparinized 
saline to maintain patency. Rats were allowed at least 5 days to recover from surgery; 
during this time rats had unrestricted access to food and water.  
Testing Procedures 
  There were two phases (I and II) within each of the three separate experiments 
conducted (see Table 3.1 for schematic overview). Phase I consisted of 5 daily sessions 
and was followed by phase II, which consisted of 10 daily sessions. The punishment 
procedures used in all sessions was the same one described for the choice training 
session, with the exception of the consequences of responding on each lever.  In each 
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90 min session, the maximum number of choice trials that could be completed was 43, 
and each ITI was 120 s long.  
Phase I 
 Experiments 1-4: Acquisition of responding on a lever that delivered sucrose. 
After recovery from surgery, rats received 5 daily sessions to acquire responding on a 
lever that delivered a sucrose pellet. The lever a rat made fewer responses on during 
the choice training session was designated lever 1, and the consequence of responding 
on lever 1 was the delivery of a sucrose pellet. The lever a rat made more responses on 
during the choice training session was designated lever 2, and responding on lever 2 
resulted in the delivery of a saline injection.  
Phase II 
 Experiment 1. Evaluating the effects of pairing nicotine (0.01, 0.03, and 0.1 
mg/kg per injection) and saline injection with sucrose delivery on lever 
responding, which delivered either sucrose+injection, or sucrose alone. In phase II 
the consequence of responding on lever 1 was changed from the delivery of a sucrose 
pellet to the delivery of a sucrose pellet paired with a simultaneous injection (i.e., 
sucrose+injection) of nicotine (0.01, 0.03, or 0.1 mg/kg per injection) or saline, and the 
consequence of responding on lever 2 was changed from the delivery of a saline 
injection to the delivery of a sucrose pellet (n=6-7/group).  
 Experiment 2. Evaluating the effects of pairing nicotine injection (0.03, 0.1, 
and 0.18 mg/kg per injection) with sucrose delivery on lever, which delivered 
either sucrose+injection, or nothing. In phase II the consequence of responding on 
lever 1 was changed from the delivery of a sucrose pellet to the delivery of 
sucrose+injection of nicotine (0.03, 0.1 or 0.18 mg/kg per injection), and the 
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consequence of responding on lever 2 was changed from delivery of a saline injection 
to the delivery of nothing (i.e., null consequence) (n=6/group).  
 Experiment 3. Evaluating the effect of delaying nicotine (0.1 and 0.18 
mg/kg per injection) and saline injections paired with sucrose delivery on lever 
responding, which delivered either sucrose injection, or nothing. In phase II, the 
consequence of responding on lever 1 was changed from delivery of a sucrose pellet to 
the delivery of sucrose+injection of nicotine (0.1 or 0.18 mg/kg per injection) or saline, 
and the consequence of responding on lever 2 was changed from delivery of a saline 
injection to the delivery of nothing. For every response made on lever 1, the injection 
was either administered simultaneously with sucrose delivery (no delay), or 60 s after 
sucrose delivery (delay). Each injection delivery condition was conducted for 5 
consecutive sessions, and the order of the conditions conducted was counterbalanced 
within groups (n=5-6/group).  
 Experiment 4. Evaluating response-independent delivery of IV nicotine 
injection on lever responding. In phase II, the consequence of responding on lever 1 
continued to deliver sucrose, while the consequence of responding on lever 2 was 
changed from the delivery of saline to the delivery of nothing. Within each session 
conducted, rats could respond on lever 1 or lever 2 while being administered a 
continuous 90 min infusion of response-independent nicotine totaling 1.0 or 1.8 mg (or 
saline) in a volume of 4.8 ml. Three independent groups were used to test each dose of 
nicotine or saline administered (n=6/group). 
Drugs 
 (-)-Nicotine hydrogen tartrate salt was obtained from Sigma-Aldrich (St. Louis, MO) and 
dissolved in 0.9% saline solution. Response-dependent and –independent nicotine or 
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saline injections were administered intravenously under all conditions studied, and drug 
doses were calculated on the basis of the salt form of the drug.  
Data Analysis  
 For all experiments, the dependent variable measured in each session was the 
number of responses made on each lever. One-way repeated measures ANOVAs were 
used to determine if changing the consequence of responding on each lever affected 
lever responding across sessions. To determine if lever responding was different among 
groups that received different injections (either by drug or dose), responses made on 
each lever across all sessions in phase II were averaged by group, and the mean 
responses were compared using two-way ANOVAs. Significant ANOVAs were followed 
by Bonferroni post hoc tests. All statistical tests used an alpha of 0.05, two-tailed. 
Analyses were performed using Prism 6.0 (GraphPad Software, La Jolla, CA, USA).   
 
Results 
 Experiments 1-4: Acquisition of responding on lever 1 (sucrose). All rats 
readily acquired lever responding, with all responses made almost exclusively on lever 
1 (sucrose) compared to lever 2 (saline injection) (data not shown). By session 5, group-
averaged responses made on lever 1 in Experiments 1, 2, 3, and 4 was 39.9±0.3, 
38.2±1.0, 38.3±0.5, and 39.2±1.1, respectively. Group-averaged responses made on 
lever 2 in Experiments 1, 2, 3, and 4 was 1.8±0.3, 3.5±1.3, 4.5±0.4, and 2.6±1.1, 
respectively. This pattern of responding indicates that responding on lever 1 was 
maintained by the reinforcing effect of sucrose.  
 Experiment 1. Effects of pairing nicotine or saline injection with sucrose 
delivery on lever responding, which either delivered sucrose+injection, or sucrose 
alone. When an injection was delivered with sucrose in phase II, responding on lever 1 
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generally decreased as responding on lever 2 increased (Fig. 3.1a-c), and the extent to 
which responding decreased on lever 1 and increased on lever 2 was dependent on the 
dose of nicotine delivered with sucrose (Fig 3.2). In the saline group, changing the 
consequences of responding on lever 1 and lever 2 changed responding on both lever 
1 [F(10, 50)=2.30, p=0.02] and lever 2 [F(10, 50)=4.61, p=0.02]. Rats made fewer 
responses on lever 1 in session 12 and 14 compared to session 5, and made more 
responses on lever 2 in session 12 and 14 compared to session 5 (Fig. 3.1a). In the 0.01 
mg/kg nicotine group, changing the consequences of responding on lever 1 and lever 2 
in phase II changed responding on both lever 1 [F(10, 60)=4.70, p<0.0001] and lever 2 
[F(10, 60)=4.61, p<0.0001]. Rats made fewer responses on lever 1 in each session from 
12 to 15 compared to session 5, and made more responses on lever 2 in each session 
from 13 to 15 compared to session 5 (Fig. 3.1b). In the 0.03 mg/kg nicotine group, 
changing the consequences of responding on lever 1 and lever 2 in phase II changed 
responding on both lever 1 [F(10, 60)=6.41, p<0.0001] and lever 2 [F(10, 60)=6.86, 
p<0.0001]. Rats made fewer responses on lever 1 in each session from 10 to 15 
compared to session 5 and made more responses on lever 2 in each session from 10 to 
15 compared to session 5 (Fig. 3.1c). In the 0.1 mg/kg nicotine group, changing the 
consequences of responding on lever 1 and lever 2 in phase II changed responding on 
both lever 1 [F(10, 60)=4.81, p<0.0001] and lever 2 [F(10, 60)=4.81, p<0.0001]. Rats 
made fewer responses on lever 1 across each session from 6 to 15 compared to 
session 5 and made more responses on lever 2 in each session from 6 to 15 compared 
to session 5 (Fig. 3.1d). Between-subjects analysis revealed that the average number of 
responses made across sessions 6-15 in phase II was not different among groups. 
However, there was a difference in responding on levers such that as the unit dose of 
nicotine injection increased, responses for lever 1 decreased, while responding on lever 
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2 increased [main effect of lever: F(1, 46)=24.75 p<0.0001; lever x dose interaction: 
F(3,46)=6.15, p=0.001] (Fig. 3.2). The 0.1 mg/kg nicotine group made the fewest 
responses on lever 1 (sucrose+injection) and the most responses on lever 2 (sucrose) 
compared to the saline group, which made the most responses on lever 1 and the 
fewest responses on lever 2.  
 Experiment 2. Effects of pairing nicotine injection with sucrose delivery on 
lever responding, which either delivered sucrose+injection, or nothing. Each group 
responded almost exclusively on lever 1, with few or no responses made on lever 2 
across sessions 5-15 (Fig. 3.3a-c). In the 0.03 mg/kg nicotine group, pairing an injection 
of 0.03 mg/kg nicotine with sucrose delivery did not change responding on lever 1 in 
phase II (Fig. 3.3a). However, in the 0.1 mg/kg nicotine group, pairing an injection of 0.1 
mg/kg nicotine with sucrose delivery changed responding on lever 1 [F(10, 50)=13.57, 
p<0.0001] (Fig. 3.3b). When the consequence of responding on lever 1 was changed 
from sucrose to sucrose+injection, rats made fewer responses on lever 1 across each 
session from 7 to 15 as compared to session 5 (Fig. 3.3b). In the 0.18 mg/kg nicotine 
group, pairing an injection of 0.18 mg/kg nicotine with sucrose delivery changed 
responding on lever 1 [F(10, 50)=14.08, p<0.0001]. When the consequence of 
responding on lever 1 was changed from sucrose to sucrose+injection, rats made fewer 
responses on lever 1 across each session from 6 to 15 as compared to session 5 (Fig. 
3.3c). Additionally, while there was a change in responding on lever 2 in session 9 [F(10, 
40)=2.39, p=0.02], responding in session 9 was not significantly different from 
responding in session 5. Between-subjects analysis revealed that the average number 
of responses made across sessions 6-15 in phase II was different among groups [main 
effect of dose: F(2, 28)=35.95, p<0.0001]. The number of responses made on lever 1 
was affected by the dose of nicotine delivered [main effect of lever: F(2, 28)=35.95, 
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p<0.0001; lever x dose interaction: F(2, 28)=29.64, p<0.0001] (Fig. 3.4). Responding on 
lever 1 was dependent on dose with rats that received the highest unit dose of nicotine 
making the least amount of responses (0.18<0.1<0.03 mg/kg).  
 Experiment 3. Effect of delaying nicotine injection on lever responding, 
which either delivered sucrose injection, or nothing. Rats responded almost 
exclusively on lever 1 (sucrose+injection) and made few or no responses on lever 2 
(nothing) in phase II. However, responding rates on lever 1 (sucrose+injection) were 
different among groups [main effect of dose: F(2, 30)=63.31,  p<0.0001], with 
responding affected by the unit dose of nicotine delivered and the immediacy of the 
injection delivery [main effect of delay: F(1, 30)=12.45, p=0.001; delay x dose: F(2, 
30)=3.920, p=0.03] (Fig. 3.5). Under the no-delay condition, both the 0.1 and 0.18 
mg/kg nicotine groups made fewer responses on lever 1 compared to the saline group, 
and the 0.18 mg/kg nicotine group made fewer responses than the 0.1 mg/kg nicotine 
group. Under the delay condition, the 0.18 mg/kg nicotine group made fewer responses 
on lever 1 compared to both the saline and the 0.1 mg/kg nicotine groups. Both the 0.1 
and 0.18 mg/kg nicotine groups made more lever responses when the injection was 
delayed than when there was no delay. However, in the saline injection group, lever 
responding did not differ between delay and no-delay injection conditions.  
 Experiment 4. Effect of response-independent delivery of IV nicotine 
injection on lever responding. The delivery of response-independent saline or nicotine 
totaling 1.0 mg per session did not change lever responding across sessions 6-15 as 
compared to when no infusion was delivered in session 5 (Fig. 3.6a and 3.6b). However, 
response-independent delivery of 1.8 mg nicotine per session changed responding on 
lever 1 across sessions [F(10, 50)=17.90, p<0.0001] (Fig. 3. 6c). Rats made fewer 
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responses on lever 1 on each session from 8 to 15 as compared to responses made on 
session 5 when no infusion was administered.  
 Fig. 3.7 displays average responses (across session 6-15) that were made by 
each group on lever 1 that delivered sucrose, and lever 2, which delivered nothing. The 
number of responses made on lever 1 vs. lever 2 differed [main effect of lever: F(1, 
30)=1677, p<0.0001] with the number of responses made affected by the dose of 
response-independent nicotine administered per session [main effect of dose: F(2, 
30)=204.0, p<0.0001; lever x dose: F(2, 30)=208.7, p<0.0001]. Rats made more 
responses on lever 1 than on lever 2. Responding on lever 2 did not differ among 
groups, but rats that received a dose of 1.8 mg nicotine made fewer responses on lever 
1 compared to rats that received a dose of 1.0 mg nicotine or saline. Responses made 
on lever 1 did not differ between the saline and 1.0 mg nicotine group. 
 
Discussion 
 The purpose of the present study was to examine the punishing effects of IV 
nicotine injection on sucrose-reinforced lever responding. In general, sucrose served as 
a reinforcer of lever responding, whereas nicotine served as a punisher of lever 
responding. Punishment by nicotine was dependent on the unit dose of injection 
delivered, the immediacy of injection delivery upon a lever response, and the behavioral 
alternative to punished responding. Additionally, the cumulative doses of nicotine 
delivered in punishment situations were not likely due to direct suppressant effects, 
since comparable doses given response-independently did not affect sucrose-
reinforced lever responding.   
Punishing effects of nicotine   
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 When rats were presented with levers that delivered either sucrose+injection or 
sucrose only, all rats decreased their responding on the sucrose+injection lever whether 
the injection delivered was nicotine or saline. However, the degree to which initial and 
overall responding on the sucrose+injection lever was reduced was directly related to 
the dose of nicotine delivered per response, with greater reduction observed as the 
dose of nicotine increased. These findings have also been observed in squirrel monkeys 
trained to respond on a lever that delivered food (Goldberg and Spealman 1983). The 
decreases in responding on the sucrose+injection lever were also accompanied by 
increases in responding on the alternative lever that delivered sucrose alone. The 
amount of responding that increased on the sucrose lever reflected the decrease in 
responding on the sucrose+injection lever (Fig. 3. 2). As a result of the reallocation of 
responses, rats always made the maximum number of responses per session. 
Therefore, the nicotine dose-dependent decreases in responding on the 
sucrose+injection lever could not be attributed to direct suppressant effects. This is the 
first study that we are aware of to demonstrate that nicotine not only functioned to 
punish responding leading to its delivery, but also resulted in an increase in responding 
on the lever that delivered an “unpunished” positive reinforcer. Reallocation of 
responding resulting from punishment has been reported in studies that used choice 
procedures to examine punishment of cocaine-reinforced (Johanson 1977) and food-
reinforced (Azrin et al. 1965) behavior by electric shock, and punishment of food-
reinforced behavior by IV histamine injections (Woolverton 2003; Podlesnik et al 2010). 
But while punishment resulted in reallocation of behavior in these studies, behavioral 
histories on the levers were not considered, even though they may be important in 
determining the effects of punishment. For instance, the increases in responding on the 
sucrose lever in phase II may have been due in part to the fact that the consequence of 
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responding on the lever was changed from saline injection to sucrose, which may 
explain why responding increased on the respective lever among the saline injection 
group. 
Attenuation of the punishing effect of nicotine 
 Nicotine dose-dependent decreases in responding on the sucrose+nicotine 
lever were attenuated when the alternative response consequence was null, as 
compared to when it was sucrose only. For instance, pairing an injection of 0.03 mg/kg 
nicotine with sucrose delivery did not punish responding on the sucrose+nicotine lever 
when the consequence of responding on the alternative lever was null (Fig. 3. 3a). While 
it could be argued that an injection of 0.03 mg/kg nicotine is not a behaviorally active 
dose under these conditions, the same unit dose of nicotine punished responding on 
the sucrose+nicotine lever when responding on the alternative lever delivered sucrose 
(Fig. 3.1c). Furthermore, while unit doses of 0.1 and 0.18 mg/kg nicotine decreased 
responding on the sucrose+nicotine lever, the degree to which responding decreased 
with each dose was similar to what was observed with unit doses of 0.03 and 0.1 
mg/kg nicotine, respectively, when responding on the alternative lever delivered 
sucrose only. The degree to which attenuation of punished responding occurs indicates 
that not having a positively reinforced behavioral alternative decreased the dose-
dependent effects of nicotine by a quarter log. Other studies using choice procedures 
have demonstrated that having an equivalent reinforcer that is unpunished as the 
consequence of the behavioral alternative may provide a more sensitive measurement 
of punishment, such that a lower intensity of electric shock (Azrin and Holz 1966) or a 
smaller dose of IV histamine (Woolverton 2003) was needed to punish behavior when 
no positively reinforced behavioral alternative was available.  
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 The punishing effects of 0.1 and 0.18 mg/kg per injection nicotine observed 
when the alternative response consequence is null could be further attenuated if the 
nicotine injection delivered with sucrose was delayed by 60 s after a response was 
made. The finding that delaying the delivery of nicotine results in an attenuation of 
punishment agrees with findings that the punishing effects of a stimulus decreases as 
the time interval after a response made for the punishing stimulus increases (see Azrin 
and Holz 1966). For example, Woolverton et al. (2012) found that delaying the delivery 
of response-contingent histamine injections decreased punishment of cocaine-
reinforced lever responding in rhesus monkeys. These findings suggest that a punisher 
is most effective when it is administered immediately upon a response-contingent 
behavior.  
Control for direct-suppressant effects 
 The degree to which nicotine punishes lever responding in this study has been 
seemingly related to the dose of nicotine. However, results from delaying nicotine 
injections suggests otherwise. When the delivery of the nicotine injection paired with 
sucrose was delayed for 60 s after a response was made, rats increased their 
responding on the lever that delivered nicotine with sucrose as compared to when there 
was no delay. Total daily nicotine intake was therefore greater under the delayed 
injection condition. While delaying the injection could have interfered with the spacing 
of nicotine injections (e.g., time between sequential nicotine injections would be 
shorter), programming the 120 s ITI to begin after a response was made ensured that 
response-dependent injections were delivered at least 120 s between responses 
regardless of whether the injection was administered immediately or 60 s after a 
response was made. Therefore, the finding that more lever responses are made when 
larger doses of total nicotine intake occurs under the delayed nicotine injection 
	  	   57	  
condition suggests that the behavioral effects of nicotine are neither invariable nor 
predictable solely on the basis of the drug’s inherent pharmacological qualities. 
Consideration of factors such as the contiguity (i.e., temporal proximity) between a 
response and consequence of the response being delivered may have practical 
implications in examining the behavioral effects of drugs. Examining the effects of delay 
on response-dependent drug delivery may therefore be useful in determining if a 
decrease in behavior is due to punishment (i.e., decreased responding due to the 
learned contingency) vs. direct suppression of responding. 
Punishing strength of nicotine 
 While nicotine served as a punisher in this study, responding on the 
sucrose+injection lever was not completely abolished under any of the described 
conditions. It could be argued that nicotine injections did not abolish responding on the 
sucrose+injection lever because nicotine had some reinforcing effect. The unit doses of 
nicotine used in this study have been found to be reinforcing in IV self-administration 
studies. For example, using limited-access schedules (e.g., fixed ratio schedules with 
time outs), rats pre-trained to bar press for nicotine injections will self-administer doses 
of 0.03- 0.46 mg/kg/inj of nicotine, with a total daily nicotine intake ranging from 0.46- 
to 4.6 mg/kg (Corrigall and Coen 1989; Chaudhri et al. 2005; Shoaib et al. 1997; 
Watkins et al. 1999). The decreases in responding on the sucrose+injection lever may 
therefore represent changes in behavior that would allow rats to attain a total dose of 
nicotine that is reinforcing (e.g., Corrigall and Coen 1989; Lynch and Carroll 1999). 
However, this rationalization does not explain why nicotine intake differs among groups 
that received different unit doses of nicotine (e.g., when choice was sucrose+injection 
or sucrose, the average daily nicotine intake for the 0.01, 0.03 and 0.1 mg/kg/inj 
nicotine groups were 0.30, 0.79, and 1.89 mg/kg respectively).  
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 An alternative explanation as to why some responding persists on the 
sucrose+injection lever may be due to the reinforcing effect (value) of sucrose. The 
magnitude of the reinforcer that maintains a behavior has been reported to be a 
determinant of punishment, in which behavior maintained by lower magnitude 
reinforcers is more strongly punished (Johanson 1977; Poling and Thompson 1977). It is 
possible that the unit doses of nicotine studied were mildly punishing compared to the 
highly reinforcing effect of sucrose. Therefore, in principle, responding on the 
sucrose+injection lever could have been abolished if larger doses of nicotine and/or 
smaller amounts of sucrose were used to maintain behavior. 
 Interestingly, Goldberg and Spealman (1982) reported that IV nicotine injections 
that were reinforcing in squirrel monkeys suppressed food-maintained behavior, such 
that suppression by nicotine was equivalent to suppression by electric shock, and, in 
some instances, response behavior was completely abolished. In their study, squirrel 
monkeys were able to respond on a single lever under a two-component, multiple FR 
schedule (unpunished and punished signaled components). In both components, every 
FR 30 resulted in the presentation of food, whereas in the punished component, only 
the first response in each of FR 30 produced an injection of nicotine. The deliveries of 
nicotine injections were never given concurrently with food presentation, whereas in the 
present study, nicotine injections were either given concurrently with sucrose or 60 s 
after. Methodological differences between the two studies may account for the degree 
to which nicotine punishes behavior. Using multiple schedules with different FRs for the 
delivery of sucrose and nicotine injection may be useful in determining if schedule 
control influences the punishing effects of nicotine in “choice” studies.  
Effects of response-independent IV nicotine injections 
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  Delivery of a continuous 90 min infusion of response-independent nicotine 
totaling 1.0 mg did not change sucrose-reinforced lever responding as compared to 
when no nicotine was delivered, and responding rates did not differ from those of rats 
that received saline. In contrast, sucrose-reinforced lever responding did decrease in 
rats that received a cumulative dose of 1.8 mg nicotine compared to when no nicotine 
was delivered and responding was lower than responding by rats that received 1.0 mg 
nicotine or saline. While these findings agree with the findings in which higher 
cumulative doses of drug result in decreases in self-administration behavior (see Katz 
1989), it is unclear whether the observed decrease in lever responding with the delivery 
of 1.8 mg nicotine resulted from conditioned and/or unconditioned suppressant effects. 
For instance, when rats were administered 1.8 mg nicotine for the first time in session 
6, lever responding decreased by approximately 35% as compared to when no nicotine 
was delivered, and continued to decrease with repeated response-independent nicotine 
administration. By the 10th and final administration of 1.8 mg nicotine, responding was 
almost completely suppressed. Since rats demonstrated that they were capable of 
making lever responses in session 6, this suggests that administration of 1.8 mg of 
response-independent nicotine may have resulted in both conditioned and 
unconditioned behavioral suppressant effects. Although it is unclear what is the exact 
underlying mechanisms that resulted in the observed decreases in lever responding, 
these findings are still useful because they provide a rate-limiting cumulative dose of 
nicotine in which the direct suppressant effects cannot be differentiated from the 
punishing effects. Accordingly, decreases in behavior observed with cumulative doses 
of nicotine that are equal to or lower than 1.0 mg of nicotine delivered response-
dependently are not likely due to a direct suppressant effect of nicotine. Whereas 
cumulative doses of nicotine that are greater than 1.0 mg (as observed with the 
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response-independent delivery of 1.8 mg) may have direct suppressant effects that limit 
the overall rate of responding on both levers.  
 Although a cumulative dose of 1.0 mg of nicotine was delivered in both the 
response-dependent and -independent conditions, the effects of nicotine on rates of 
lever responding were only observed in the response-dependent condition. 1.0 mg 
nicotine delivered under the response-independent condition might be behaviorally 
inactive due to the delivery method of nicotine. Under the response-independent 
condition, the cumulative 1.0 mg of nicotine was delivered as a continuous infusion, 
such that rats effectively received one injection in which the infusion rate was 1.0 mg 
nicotine per 90 min. Under the response-dependent condition, however, the cumulative 
dose of 1.0 mg nicotine was delivered in pulsatile increments, through individual 
nicotine injections of 0.1 or 0.18 mg/kg, at an infusion rate of 4-6 s. The maximum 
frequency in which the individual injections could be delivered was every 2 minutes, 
and was controlled by the rats’ responding. Differences in the delivery of nicotine could 
have altered the effects of nicotine, such that doses of nicotine and/or drug levels 
obtained under the response-dependent condition were aversive, which lead to the 
decreases in lever responding (see Katz 1989; Rose and Corrigall 1997). It has been 
suggested that the decreases in response behavior observed in preliminary 
investigations of IV nicotine self-administration studies was a result of the continuous 
reinforcement schedule that permitted high doses of nicotine to quickly accumulate 
with continuous successions of injections (see Goldberg and Spealman 1982; Corrigall 
and Coen 1989). Self-administration studies have also shown that the infusion rate at 
which IV nicotine is delivered affects the reinforcing effects of nicotine (Wakasa et al. 
1995; Sorge and Clarke 2009; Wing and Shoaib 2013). For example, in a concurrent 
FR1-FR1 choice study in which rats could respond on two concurrently available levers 
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that delivered either a dose of 15µg/kg nicotine (base) at an infusion rate of 3 s or 30 s, 
rats made significantly more responses on the lever that delivered nicotine at an 
infusion rate of 30 s (Sorger and Clarke 2009).  
 While the effects of response-dependent and independent nicotine have been 
discussed and compared in terms of the rate of nicotine delivery, it is important to note 
that the difference in the contingency of nicotine delivery may also account for 
differences in the effects of nicotine. Studies have reported significant differences in the 
effects of drugs associated with response-dependent versus response-independent 
administration (e.g., Mello and Mendelson 1970; Ator and Griffiths 1992). For instance, 
Dworkin et al. (1995) found that while response-dependent cocaine self-administration 
was reinforcing in rats, the response-independent administration of the same or similar 
dosage pattern was lethal. Therefore, while the cumulative dose of nicotine delivered 
may be related to some of the behavioral effects of nicotine that have been reported 
(e.g., Corrigall and Coen 1989), the conditions under which nicotine is delivered can 
alter the effects of the nicotine.  
Conclusions 
 This is the first study of which we are aware that demonstrates that the same 
doses of IV nicotine injections that are reported to be reinforcing in rats (Corrigall and 
Coen 1989; Chaudhri et al. 2005; Shoaib et al. 1997; Watkins et al. 1999), could also 
function to punish response behavior in the present studies. While the pharmacological 
properties of nicotine (e.g., dose-dependent effects) are important determinants of 
punishment, environmental conditions in which nicotine is self-administered (e.g., 
alternative response consequences) are also important. Therefore, consideration of the 
environmental context in which nicotine is self-administered may have practical 
implications in understanding the effects of nicotine on behavior.  
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Table 3.1. Consequences of responding on lever 1 and lever 2 in phase I and II for each 
nicotine punishment experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
 Consequences of responding on levers 
Phase I: Sessions 1-5 
 
Phase II: Sessions 6-15 
 
Lever 1 Lever 2 Lever 1 Lever 2 
Experiment 1 
Evaluating the effect of pairing nicotine 
(saline, 0.01, 0.03, or 0.1 mg/kg) injection 
with sucrose delivery  
 
sucrose saline injection  
 
sucrose+injection sucrose 
Experiment 2 
Evaluating the effect of pairing nicotine 
(0.03, 0.1, or 0.18 mg/kg) injection with 
sucrose delivery  
 
sucrose saline injection  
 
sucrose+injection nothing 
Experiment 3 
Evaluating the effect of delaying (saline, or 
0.1, 0.18 mg/kg nicotine) injection paired 
with sucrose delivery  
sucrose saline injection  
 
sucrose+injection 
or 
sucrose 
+delayed 
injection 
 
nothing 
Experiment 4 
Evaluating the effect of response-
independent nicotine (saline, 1.0 or 1.8 mg 
total) delivery on lever responding 
sucrose saline injection sucrose nothing 
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Figure 3.1 
  
Figure 3.1 Effects of pairing nicotine injection with sucrose delivery on lever 
responding that delivered either sucrose+injection or sucrose. Each graph displays 
data from individual groups that differ by the dose of nicotine or saline “injection” paired 
with sucrose delivery in phase II (a) saline, (b) 0.01 mg/kg nicotine, (c) 0.03 mg/kg 
nicotine, and (d) 0.1 mg/kg nicotine (n=6 per group). Closed and open symbols 
represent the mean (±SEM) responses made on lever 1 and lever 2, respectively. 
Legends next to the symbols listed in the table indicate the consequences of 
responding on lever 1 and lever 2 in phases I and II. *, p<0.05, **, p<0.01, ***, p<0.001, 
****, p<0.0001. Significant decrease in responses made on lever 1 as compared to 
responses made in session 5. +, p<0.05, ++, p<0.01, +++, p<0.001, ++++, p<0.0001. 
Significant increase in responses made on lever 2 as compared to responses made in 
session 5. 
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Figure 3.2 
 
Figure 3.2 Nicotine dose-dependent decreased responding on the 
sucrose+injection lever, and increased responding on the sucrose lever. Values on 
the x-axis indicate dose of nicotine or saline “injection” delivered for responses made 
on the sucrose+injection lever. Closed and open symbols represent the mean (±SEM) 
responses made on the sucrose+injection and sucrose levers, respectively, in phase II 
(n=6). *, p<0.05. Significant increase in responses made on the sucrose lever as 
compared to saline. +, p<0.05. Significant decrease in responses made on the 
sucrose+injection as compared to saline. 
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Figure 3.3 
 
Figure 3.3 Effects of pairing nicotine injection with sucrose delivery on lever 
responding that delivered either sucrose+injection, or nothing. Each graph displays 
data from individual groups that differ by the dose of nicotine “injection” paired with 
sucrose delivery in phase II: (a) 0.03 mg/kg nicotine, (b) 0.1 mg/kg nicotine and (c) 0.18 
mg/kg nicotine (n=6 per group). Closed and open symbols represent the mean (±SEM) 
responses made on lever 1 and lever 2 respectively. Legends next to the symbols listed 
in the table indicate the consequence of responding on lever 1 and lever 2 in phases I 
and II. *, p<0.05, ****, p<0.0001. Significant decrease in responses made on lever 1 as 
compared to responses made in session 5. 
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Figure 3.4 
      
    
Figure 3.4 Dose-dependent effects of nicotine injection on lever responding that 
delivered either sucrose injection, or nothing. Values on the x-axis indicate the dose 
of nicotine “injection” delivered with sucrose for responses made on lever 1. Closed 
and open symbols represent the mean (±SEM) responses made on lever 1 and lever 2, 
respectively, in phase II, (n=6). ***, p<0.001, ****, p<0.0001. Significant decrease in 
responding on lever 1 compared to 0.03 mg/kg nicotine injection condition. ##, p<0.01. 
Significant difference in responding on lever 1 between the 0.1 mg/kg nicotine and 0.18 
mg/kg nicotine conditions.  
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Figure 3.5 
   
Figure 3.5 Attenuation of the punishing effects of nicotine by delaying injection 
delivery paired with sucrose. Values on the x-axis indicate the dose of nicotine or 
saline “injection” delivered with sucrose for responses made on the sucrose+injection 
lever. Closed and open symbols represent the mean (±SEM) responses made on the 
sucrose+injection lever when injections were delayed or not delayed, respectively, in 
phase II (n=6). ****, p<0.0001. Significant decrease in responding on sucrose+injection 
lever compared to saline. #, p<0.05. Significant decrease in responding on 
sucrose+injection lever compared delayed.  
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Figure 3.6 
 
Figure 3.6 Effect of response-independent nicotine on lever responding. Each 
graph displays data from individual groups that differ by the dose of nicotine or saline 
delivered per session in phase II: (a) 0.03 mg/kg nicotine, (b) 0.1 mg/kg nicotine and (c) 
0.18 mg/kg nicotine (n=6 per group). Closed and open symbols represent the mean 
(±SEM) responses made on lever 1 and lever 2 respectively. Legends next to the 
symbols listed in the table indicate the consequences of responding on lever 1 and 
lever 2 by sessions. *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001. Significant 
decrease in responses made on lever 1 as compared to responses made in session 5.  
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Figure 3.7 
   
Figure 3.7 Dose-dependent effect of response-independent nicotine on lever 
responding. Values on the x-axis indicate the dose of nicotine or saline delivered as a 
response-independent continuous infusion during each session in phase II. Closed and 
open symbols represent the mean (±SEM) responses made on the lever 1 and lever 2, 
respectively, in phase II (n=6). ****, p<0.0001. Significant decrease in responding on 
sucrose+injection lever compared to saline.  
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Chapter 4 
Receptor mediation of the punishing effects of nicotine in rats 
 
Introduction  
 Tobacco smoking is the leading preventable cause of disease in the United 
States, resulting in over 400,000 premature deaths a year (US Department of Health 
and Human Services 2014). Despite the health consequences that result from smoking, 
over 40 million Americans continue to smoke. Among current smokers, it is reported 
that a majority want to quit, and among those who have tried to quit, most are 
unsuccessful (Center for Disease and Control and Prevention 2009). While the 
determinants of tobacco addiction are multifaceted, a large body of evidence has led to 
the widely accepted conclusion that nicotine, a primary constituent of tobacco, is “the 
drug in tobacco that causes addiction” (US Department of Health and Human Services 
1988).  
 It has been well documented that the effects of nicotine are mediated through 
its agonist actions on neuronal nicotinic acetylcholine receptors (nAChRs) that are 
found throughout the central (CNS) and peripheral nervous systems. The nAChRs are a 
functionally diverse group of ligand-gated ion channels that exist as pentamers. To 
date, there have been twelve different neuronal subunits that have been identified in 
mammalian tissues: α2-α10 and β2-β4. Combinations of these neuronal subunits make 
up the different nAChR subtypes (see Gotti and Clementi. 2004). Substantial research 
efforts has therefore been devoted to elucidating the possible roles of different 
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nAChR subtypes in mediating the effects of nicotine that regulate nicotine-taking 
behavior (see Picciotto and Kenny 2013).  
 Evidence from pharmacological studies suggests that the reinforcing effects of 
nicotine, which are thought to be important in the abuse of tobacco products (reviewed 
in US Department of Health and Human Services 2010) are mediated through the α4β2* 
subtype of nAChR (e.g., Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 2000; 
Liu et al. 2007; Le Foll et al. 2009). Accordingly, the α4β2* nAChRs have been a primary 
target for smoking cessation agents (see Benowitz 2008; Taly et al. 2009). Although the 
reinforcing effects of nicotine are important in establishing and maintaining abuse of 
tobacco, it has been suggested that self-administration of drugs of abuse may be a 
function of the relative balance between the reinforcing and aversive effects (Stolerman 
and D’Mello 1981; Katz 1989; Lynch and Carroll 2001; Riley 2011). As such, it has been 
hypothesized that along with the reinforcing effects of nicotine, aversive effects may 
also be important in determining nicotine-taking behaviors (see Benowitz 1990; Le Foll 
and Goldberg 2009). Therefore, the investigation of the nAChR subtype(s) that mediate 
the aversive effects of nicotine may also be important targets for the development of 
novel therapeutics for smoking cessation. 
 Nicotine can produce aversive effects at doses that have been found to be 
reinforcing in non-human primates (Goldberg and Spealman 1982; 1983; Spealman 
1983), rodents (Truong and Woods; unpublished data), and humans (Henningfield and 
Goldberg 1983). Interestingly, it has been suggested that the α4β2* nAChRs may be 
involved in mediating the effects of nicotine-induced conditioned taste aversion (Shoaib 
and Stolerman 1995; Shoaib et al. 2000; 2002; Gommans et al. 2000) and nicotine-
induced conditioned place aversion (Laviolette and Kooy 2003). However, recent 
findings from a molecular genetic study using self-administration procedures suggest 
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that the aversive effects of nicotine are mediated through different nAChRs that contain 
the α5* subunit  (Fowler et al. 2011). While pharmacological studies using operant 
procedures have demonstrated that nAChRs mediate the aversive effects of nicotine 
(Goldberg and Spealman 1982), and that these effects are likely being mediated by 
nAChRs in the CNS (Spealman 1983), it is unclear whether the α4β2* nAChRs are 
involved in these effects.  
 Using a punishment procedure, the purpose of this study was to examine the 
antagonism of the aversive effects of IV nicotine in rats. Examining antagonism of the 
aversive effects of IV nicotine may lead to a more general understanding of the receptor 
mediated effects of nicotine that control behavior. The antagonists used in this study 
were mecamylamine (Stone et al. 1956; Martin et al. 1989), a nicotine receptor ion 
channel blocker that is uncompetitive in its actions, and dihydro-beta-erythroidine 
(DHβE) (Williams and Robinson, 1984; Sabey et al. 1999; Shoaib et al. 2000), a 
competitive, α4β2* selective nAChR antagonist.  
Methods   
 All experimental procedures were approved by the University of Michigan 
Committee on the Use and Care of Animals and performed in accordance with the 
Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the 
National Institutes of Health. 
Subjects 
 Male Sprague-Dawley rats (300-375 g) were obtained from Harlan (Indianapolis, 
IN) and housed in a temperature- (21-23 °C) and humidity-controlled environment on a 
12-h dark/light cycle, with lights on at 7:00 A.M. Rats were housed three per cage 
during non-drug behavioral training procedures, and then individually housed after 
surgery was completed. Except during experimental sessions, rats had free access to 
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tap water and were on food-restricted diets of Purina rodent chow that maintained at 
least 80% of their pre-restriction body weights. All experiments were conducted 5-7 
days/week between 9:00 A.M and 5:00 P.M.  
Apparatus 
 Med Associates (St. Albans, VT) operant conditioning chambers and manipulanda 
were used for all experiments. Each operant conditioning chamber was approximately 
30 cm long, 24 cm wide, and 21 cm high, and was contained in a sound-attenuating 
cubicle. The front panel of each operant conditioning chamber was equipped with two 
retractable levers, 6.8 cm above the grid floor, and 1.3 cm from the side walls, with an 
array of red, yellow, and green light-emitting diodes (LEDs) above each lever. A 2.8V 
white incandescent house light was located at the top center of the rear panel. Located 
between the two levers was a magazine in which a 45 mg sucrose pellet (Bio-Serv, 
Frenchtown, NJ) could be delivered. IV drug injections were delivered by a motorized 
syringe driver (PHM-107; Med Associates) through Tygon tubing (S-54-HL, Norton 
Performance Plastics, Akron, OH) connected to a swivel that was held in place by a 
counterbalanced arm. Syringe drivers were located outside the sound-attenuating 
chamber. The duration of response-dependent injections were determined by the 
weight of each rat divided by the drug delivery pump flow rate (0.072 ml/per/s). Data 
were collected with Med Associates software.  
Non-Drug Behavioral Training Procedures 
 Rats first received one 60 min session in which they were trained to eat sucrose 
pellets from the magazine located inside the operant chamber. No levers were available 
during this time, and sucrose pellets were delivered on a random-time 60 s schedule. 
Rats then received two 60 min daily sessions in which they were trained to respond on 
both levers. In these sessions, each lever was presented individually in alternating 
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sequence. Rats were given 8 s to press the lever each time it was presented. If a 
response was made (or no response was made after 8 s), then a sucrose pellet was 
delivered, the lever retracted, and the LEDs were turned off until the lever was 
presented again. Intertrial intervals (ITIs), which are timed intervals between trials when 
no lever is available and, therefore, no responses could be made, were each 60 s long. 
Each ITI began when the lever retracted.  
 Non-drug behavioral training finished with a single 90 min “choice” training session. 
In this session, a response made on either lever delivered a sucrose pellet. The choice 
training session began with two “lever trials” followed by a series of “choice trials.” 
Lever trials were initiated when one of the two levers was randomly extended into the 
chamber with the three LEDs above the lever turned on. Rats were given 60 s to press 
the lever after it was presented. If a response was made, sucrose was delivered, the 
lever retracted, and the LEDs were turned off. If no response was made within the 60 s, 
then the lever retracted, the LEDs were turned off, and no sucrose was delivered. Lever 
trials were presented to allow rats to sample the consequence of responding on each 
lever before choice trials began. After the two lever trials were presented, choice trials 
were initiated with the simultaneous extension of both levers and the LEDs above both 
of the levers turned on. Under a concurrent fixed ratio 1- fixed ratio 1 (FR1-FR1) 
schedule, rats were presented with the opportunity to respond on one of the two 
available levers. If a response was made on either lever, sucrose was delivered, both of 
the levers retracted, all of the LEDs were turned off, and sucrose was not delivered. If 
no response occurred within 60 s, both levers retracted and all of the LEDs were turned 
off. Each ITI was 120 s long and began when the lever(s) retracted.  
Surgery 
	  	   78	  
 After non-drug behavioral training was completed, rats were surgically 
implanted with chronic indwelling IV catheters. Rats were anesthetized with ketamine 
(100 mg/kg; IP) and xylazine (10 mg/kg; IP) before a longitudinal incision was made to 
expose the femoral vein into which a catheter constructed from Micro-Renathane 
(Braintree Scientific, Inc., Braintree, MA) was inserted. The catheter was passed 
subcutaneously to an incision made between the scapulae and was then connected to 
a metal cannula that exited the skin. Catheters were flushed daily with 0.5 ml (100 U/ml) 
of heparinized saline to maintain patency. Rats were allowed at least 5 days to recover 
from surgery; during this time rats had unrestricted access to food and water.  
Evaluating DHβE and mecamylamine pretreatment on punished lever responding 
 All testing procedures began after rats recovered from surgery. The choice 
procedure used in all sessions was the same one described for the choice training 
session, with the exception of the consequences of responding on each lever. In each 
90 min session, the maximum number of choice trials that could be completed was 43, 
and each ITI was 120 s long.  
 Rats received 5 daily sessions to acquire responding on a lever that delivered a 
sucrose pellet. The lever on which a rat made fewer responses during the choice 
training session was designated lever 1, and the consequence of responding on lever 1 
was the delivery of a sucrose pellet. The lever on which a rat made more responses 
during the choice training session was designated lever 2, and responding on lever 2 
resulted in the delivery of nothing.  
 After the 5 sessions were conducted, the consequence of responding on lever 1 
was changed from delivery of sucrose to the delivery of sucrose paired with an 
intravenous injection of nicotine (0.1 or 0.18 mg/kg per injection) or saline, while the 
consequence of responding on lever 2 remained the delivery of nothing. To evaluate 
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DHβE and mecamylamine pretreatment on punished lever responding, the pairing of a 
nicotine or saline injection with sucrose delivery was alternated sequentially across 
sessions, with examination of 0.1 mg/kg nicotine completed first before 0.18 mg/kg 
nicotine was evaluated. DHβE (vehicle, 1.0, 3.2, and 5.6 mg/kg; s.c.) and 
mecamylamine (vehicle, 0.1, 0.3, 1.0 mg/kg; s.c.) pretreatments were administered in 
the home cage 15 min before the start of the test session. Each antagonist treatment 
was separated by at least 2 days. The order of DHβE and mecamylamine 
pretreatments, and administration of each antagonist dose were counterbalanced (n=7).  
Drugs  
 (-) -Nicotine hydrogen tartrate salt, DHβE and mecamylamine were obtained 
from Sigma-Aldrich (St. Louis, MO). All drugs were dissolved in 0.9% saline solution 
and doses were calculated on the basis of the salt form of the drug. Doses of DHβE and 
mecamylamine were chosen based on reported behavioral activity in rats (Jutkiewicz et 
al. 2011). 
Data Analysis 
 The dependent variable measured in each session was the number of responses 
made on each lever. Two-way ordinary ANOVAs were used to determine if antagonist 
pretreatments (mecamylamine or DHβE) affected responding on lever 1 with the within-
subjects factors of antagonist dose and dose of nicotine delivered with sucrose (saline 
vs. 0.1 vs. 0.18 mg/kg nicotine). Significant ANOVAs were followed by Bonferroni post 
hoc tests. All statistical tests used an alpha of 0.05, two-tailed. Analyses were 
performed using Prism 6.0 (GraphPad Software, La Jolla, CA, USA). 
 
Results 
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 When rats were given 5 sessions to respond on levers that delivered sucrose or 
nothing, rats readily increased their responses on lever 1 (sucrose) while decreasing 
their response on lever 2 (nothing). By session 5, averaged responses made on lever 1 
was 38.7±0.9, whereas averaged responses made on lever 2 was 3.2±0.9. This pattern 
of responding indicated that responding on lever 1 was maintained by the reinforcing 
effect of sucrose. When the consequence of responding on lever 1 changed to include 
the delivery of an injection of nicotine or saline, responses continued to be made 
exclusively on lever 1 as compared to lever 2. However, the number of responses made 
on lever 1 was affected by the dose of nicotine delivered with sucrose [F(2,18)=38.39, 
p<0.0001]. Post hoc tests revealed that responding on lever 1 was dependent on dose 
of nicotine delivered with sucrose, such that rats that received the highest unit dose of 
nicotine made the fewest responses (saline>0.1>0.18 mg/kg) (data not shown). 
 When mecamylamine pretreatments were administered, responding on lever 1 
differed by the dose of nicotine injection paired with sucrose delivery [main effect of 
nicotine dose: F(2, 72)=119.5, p<0.0001], which was affected by dose of mecamylamine 
treatment [main effect of mecamylamine: F(3,72)=10.68, p<0.001; nicotine dose x 
mecamylamine: F(6, 72)=4.463, p=0.0007] (Fig. 4.1). Post hoc tests revealed that 
pretreatments with mecamylamine compared to vehicle did not affect responding on 
lever 1 when it delivered a saline injection with sucrose. Pretreatment with all doses of 
mecamylamine attenuated the punishing effect of 0.1 mg/kg nicotine, such that 
responding on lever 1 did not differ from trials in which the injection delivered was 
saline. Mecamylamine pretreatment also decreased the punishing effect of 0.18 mg/kg 
nicotine, such that rats treated with 0.3 or 1.0 mg/kg mecamylamine made more 
responses on lever 1 compared to vehicle treated rats, but responding on lever 1 was 
lower than when the injection delivered was saline. 
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 Pretreatments with DHβE (1.0, 3.2, and 5.6 mg/kg) did not affect responding on 
lever 1 when the injection delivered with sucrose was saline or 0.1 mg/kg nicotine 
compared to vehicle treatment (Fig. 4.2). Additionally, pretreatment with 5.6 mg/kg 
DHβE did not affect responding on lever 1 when the injection delivered with sucrose 
was 0.18 mg/kg nicotine compared to vehicle treatment (data not shown). However, the 
dose of nicotine injection delivered with sucrose affected responding on lever 1 [main 
effect of injection type: F(1, 47)=92.49, p<0.0001] with fewer responses made on lever 1 
when 0.1 mg/kg nicotine was delivered with sucrose compared to when saline was 
delivered with sucrose.  
 
Discussion 
 The purpose of the present study was to determine whether pretreatments with 
nAChR antagonists altered the punishing effects of IV nicotine injections. The degree to 
which IV nicotine injections functioned to decrease sucrose-reinforced lever responding 
was related to the dose of nicotine, with greater decreases in responding observed with 
larger doses of nicotine.  The finding that rats increased their responding on a lever that 
delivered the same unit doses of nicotine with sucrose when the delivery of nicotine 
was delayed for 60 s (see Chapter 3) suggests that the decrease in lever responding 
observed under the present conditions is not a result of direct suppressant effects, but 
due to a punishing effect of nicotine. Pretreatments with the non-selective antagonist, 
mecamylamine, resulted in the attenuation of the punishing effects of nicotine on 
sucrose-reinforced lever responding, whereas the selective α4β2* nAChR antagonist, 
DhβE, had no effects on responding. While this is not the first study to indicate that the 
punishing effects of nicotine are mediated by nAChRs (Goldberg and Spealman 1982), 
it is the first to demonstrate that the punishing effects of IV nicotine are not mediated by 
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the α4β2* nAChRs subtype, which are believed to mediate the reinforcing effects of 
self-administered nicotine (Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 
2000; Liu et al. 2007; Le Foll et al. 2009). 
Mecamylamine pretreatments on punished lever responding 
 Pretreatment with doses of 0.1-1.0 mg/kg mecamylamine had no effect on lever 
responding when saline injections were delivered with sucrose, but pretreatment with 
these doses of mecamylamine completely blocked the punishing effects of 0.1 mg/kg 
nicotine equivalently such that responding on the sucrose+injection lever did not differ 
from responding when the injection delivered with sucrose was saline. However, 
pretreatments with the same doses of mecamylamine only partially blocked the 
punishing effects of 0.18 mg/kg nicotine. The degree to which the punishing effects of 
0.18 mg/kg nicotine were attenuated depended on the dose of mecamylamine 
administered, with attenuation increasing with dose of mecamylamine. Pretreatment 
with doses of 0.1-1.0 mg/kg mecamylamine therefore resulted in a rightward shift in the 
dose response function of nicotine, suggesting that the effects of mecamylamine were 
surmountable. This indicates that the punishing effects of nicotine in rats are mediated 
by nAChRs, which is consistent with other studies that reported that mecamylamine 
increased food-reinforced lever responding that had been punished by IV nicotine 
injections (Goldberg and Spealman 1982), and decreased responding that was 
maintained by the postponement of IV nicotine injections (Spealman 1983).  
DHβE pretreatments on punished lever responding 
 While DHβE has been reported to block the effects of nicotine-induced 
conditioned taste aversion (Shoaib et al. 2000; 2002; Gommans et al. 2000) and 
unbiased conditioned place aversion (Laviolette and Kooy 2003), pretreatments with 
DHβE in the present study did not alter aversive effects of nicotine as measured by 
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punishment. It is possible that differences in the cumulative dose of nicotine (0.2-2.0 
mg/kg) administered in the conditioned taste aversion studies (Shoaib et al. 2000; 
Gommans et al. 2000) and the present study (≥2.8 mg/kg) may account for the 
differences in the effects of DHβE, such that the higher doses of nicotine self-
administered could not be antagonized. However, the doses of DHβE used in the 
present study were comparable to the ones used in the conditioned taste aversion 
studies (Shoaib et al. 2000, Gommans et al. 2000). This suggests that while the α4β2* 
nAChRs are involved in mediating the effects of nicotine-induced conditioned taste 
aversion and nicotine-induced conditioned place aversion, they are not involved in 
mediating the punishing effects of nicotine. The negative results obtained with DHβE 
treatment also provides additional evidence that demonstrates that lever responding is 
not being maintained by a reinforcing effect of nicotine, since it is thought that the 
reinforcing effects of self-administered nicotine are mediated through the α4β2* nAChR 
subtype (Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 2000; Liu et al. 
2007). Implications for the development of pharmacotherapies in treatment of 
tobacco abuse 
 Findings from pretreatments with mecamylamine and DHβE suggest that the 
punishing effects of nicotine are mediated by a population of nAChR subtype(s) that do 
not include the α4β2* nAChRs receptors. While the identification of the nAChR 
subtype(s) that mediate the aversive effects of response-contingent nicotine has yet to 
be established, it has been proposed that nAChRs that contain the α5 subunit may be 
involved in mediating the aversive effects of nicotine (Fowler et al. 2011). In this study, 
α5 knockout mice showed increased nicotine self-administration at the high unit doses 
found on the descending limb of the dose-response curve of nicotine self-
administration, which are believed to have aversive properties that may serve to limit 
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intake (e.g., Katz 1989; Rose and Corrigall 1997). Development of antagonists that are 
selective at the α5 subunit may be useful in elucidating the nAChR(s) that may be 
involved in the aversive effects of nicotine that may limit its intake. However, in 
principle, DhβE or a pharmalogical equivalent that antagonizes the reinforcing effects of 
nicotine, but not the aversive effects of self-administered nicotine, may be a useful 
pharmacotherapy in treatment of tobacco abuse. While it is not known whether 
selective nicotinic antagonists would be a useful aid in smoking cessation treatments in 
humans, receptor selective antagonists have been useful pharmacotherapies for opioid 
abuse (Comer et al. 2002, 2006; Sullivan et al. 2006; Lobmaier et al. 2008). 
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Figure 4.1 
 
Figure 4.1 The effects of mecamylamine pretreatment on nicotine dose-dependent 
punished lever responding. Legends to the right of the open symbols indicate the 
pretreatment dose of mecamylamine. Dose of nicotine or saline injection delivered with 
sucrose is indicated on the x-axis. ++, p<0.01.  ++++, p<0.0001. Significant decrease in 
lever responding compared to vehicle pretreatment when injection of saline is delivered 
with sucrose. *, p<0.05, ****, p<0.0001. Significant increase in lever responding 
compared to vehicle treatment when dose of nicotine delivered with sucrose is 0.18 
mg/kg.  
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Figure 4.2 
 
Figure 4.2 Responding on the lever that delivered sucrose+ injection of saline or 
0.1 mg/kg nicotine with DHβE pretreatment. Legends to the right of the open 
symbols indicate the pretreatment dose of DhβE. Dose of nicotine or saline injection 
delivered with sucrose is indicated on the x-axis. 
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Chapter 5 
General discussion 
 
 Tobacco products contain thousands of chemicals, but nicotine, a constituent of 
tobacco, is regarded as the psychoactive drug responsible for tobacco addiction (see 
US Department of Health and Human Services 2010).  For instance, IV self-
administration studies have clearly demonstrated that nicotine functions as a reinforcer 
in both non-human (e.g., Henningfield and Goldberg 1983b; Corrigall and Coen 1989; 
Donny et al. 1995; Le Foll and Goldberg 2007) and human subjects (e.g., Henningfield 
and Goldberg 1983b; Ator and Griffiths 1983; Harvey et al. 2004). In addition to IV 
nicotine, humans will also self-administer intranasal nicotine (Perkins et al. 1996) and 
use medicinal nicotine gum (Hughes et al. 1990). And while it is recognized that the 
effects of nicotine that contribute to tobacco addiction are diverse, it is widely accepted 
that the reinforcing effects of nicotine contribute greatly to the development and 
maintenance of its abuse in humans (Young and Herling 1986; Ator and Griffths 2003). 
Nevertheless, it is unclear why certain people become heavy smokers (i.e., people who 
smoke ≥ 2 packs of cigarettes per day), while others smoke intermittently, and still 
others try tobacco, but never develop a “habit” despite repeated exposure to nicotine. 
These observations may indicate that the reinforcing effects of nicotine may not 
account for all nicotine-taking behaviors. 
 It has been proposed that the rates at which drugs of abuse such as nicotine are 
self-administered may be influenced by aversive properties of the drug (see Cappell 
and Le Blanc 1979; Goudie AJ  1979; Russell 1979; Stolerman and D’Mello 1981; Katz 
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1989; Rose and Corrigall 1997; Le Foll and Goldberg 2009). For example, research with 
squirrel monkeys have demonstrated that the same doses of nicotine which will 
maintain self-administration (Goldberg et al. 1981; Goldberg and Spealman 1982; 
Spealman and Goldberg 1982) could also function to dose-dependently punish food-
reinforced lever responding such that the punishing effects of nicotine were effectively 
equivalent to electric shocks in which both stimuli functioned to decrease food-
reinforced responding by over 70% (Goldberg and Spealman 1982; 1983). It has also 
been reported that IV nicotine injections can also maintain lever responding to avoid its 
scheduled injection in both squirrel monkeys (Spealman 1983) and smokers 
(Henningfield and Goldberg 1983a).  
 However, it is unclear whether the aversive effects of nicotine described in these 
studies were unique to the conditions under which they were studied, or whether 
nicotine functioned more generally as an aversive stimulus. For instance, in the 
punishment procedures used by Goldberg and Spealman (1982; 1983), the first 
response in each FR30 produced an injection of nicotine and the rate in which nicotine 
injections could be delivered was limited only by the monkey’s responding. Whereas in 
the self-administration procedures, nicotine was delivered either under a fixed-interval 
or second order schedule in which the rate of nicotine delivery was limited by either the 
schedule of nicotine delivery and/or programmed time-outs (Goldberg et al. 1981; 
Goldberg and Spealman 1982; Spealman and Goldberg 1982). Accordingly, Goldberg 
and Spealman (1982; 1983) suggested that the same doses (10-30 µg/kg) of nicotine 
that functioned to punish lever responding could also reinforce lever responding 
because of differences in the schedules in which nicotine was delivered (i.e., the 
arrangement of contingencies between responding and delivery of drug) (Goldberg et 
al. 1981; Goldberg and Spealman 1982; Spealman and Goldberg 1982). These studies 
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indicated that nicotine can control behavior in divergent ways, and suggested that the 
nature of the behavioral effects of nicotine may depend on both the pharmacological 
and environmental conditions in which nicotine is administered.  
 Prior to the work presented herein, our understanding of the aversive effects of 
nicotine on self-administration behavior were limited to the studies described above, in 
which determinants of nicotine punishment had only begun to be examined. The 
present studies provide strong evidence to support the hypothesis that nicotine has 
aversive effects that may serve to limit its self-administration, such that nicotine 
functions similarly to other functional punishers, and that the α4β2* nAChR receptors, 
which are believed to be involved in mediating the reinforcing effects of nicotine 
(Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 2000; Liu et al. 2007; Le Foll 
et al. 2009) are not involved in mediating the punishing effects of nicotine. In addition, 
the IV drug punishment procedures developed for these studies may be useful in 
examining aversive effects of other drugs. 
 
Aversive Stimulus Effects of Nicotine 
  The aversive effects of nicotine that limit rates of self-administration are 
generally believed to occur with high doses and/or accumulated drug levels (see Katz 
1989; Collins 1990; Rose and Corrigall 1997). Accordingly, it has been suggested that in 
early nicotine self-administration studies that used continuous schedules of 
reinforcement fail to maintain stable rates of responding because the relatively high 
frequency in which injections can be delivered made nicotine aversive compared to the 
reinforcing effects observed with second-order schedules with programmed time-outs 
Goldberg et al. 1981; Corrigall and Coen 1989). For example, Corrigall and Coen (1989) 
were the first to clearly demonstrate that IV nicotine was reinforcing in rats by using a 
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FR5, with a 60 s time-out schedule, in daily 60-min sessions. It was suggested that 
limiting scheduled access to nicotine led to higher and more stable rates of nicotine 
self-administration because it mitigated the direct and/or aversive effects of nicotine 
that are believed to limit rates of self-administration. However, the results presented in 
Chapter 3 and Chapter 4 provide strong evidence that while the conditions under which 
nicotine is studied may influence the behavioral effects of nicotine; nicotine may 
function more broadly as an aversive stimulus than as a reinforcer. 
 For instance, doses of nicotine that fall on both the ascending and descending 
limb of the typical inverted U-shaped dose-response curve of nicotine self-
administration obtained from rats (Corrigall and Coen 1989; Shoaib et al. 1997; Watkins 
et al. 1999; Chaudhri et al. 2005) was able to punish sucrose-reinforced responding in 
the studies reported in Chapter 3 and Chapter 4. Additionally, nicotine was punishing 
despite using a schedule of nicotine delivery (FR1, with a 120s ITI, in daily-90 min 
sessions) that limits the frequency of nicotine injections similarly to self-administration 
procedures (e.g., Corrigall and Coen 1989; Donny et al 1995; Shoaib et al. 1997; 
Valentine et al. 1997). Furthermore, the punishing effects of nicotine were sensitive to 
manipulation of experimental parameters that included dose of nicotine, choice vs. non-
choice situations, and the delay of scheduled response-dependent nicotine delivery, 
which demonstrates that the punishing effects of nicotine are equivalent to punishers 
such as electric shock or IV histamine injections.  
 
Punishment procedures to examine the aversive effects of IV drugs 
 Although punishment procedures have been developed to examine the aversive 
effects of nicotine (Goldberg and Spealman 1982; 1983), the procedures described 
herein may also be useful in further examining the aversive effects of IV nicotine and 
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other drugs of abuse, such that these procedures may provide a more sensitive 
measure of the punishing effects of drugs than single operant conditions alone. For 
example, in the choice condition, it was found that the doses of nicotine that were 
needed to punish sucrose-reinforced responding were lower than if no positively 
reinforced behavioral alternative was available. Furthermore, because rats were able to 
allocate responding between punished and unpunished responses, this contingency 
provided a control within the experiment to determine whether decreases in rates of 
punished responding were due to punishment or direct suppressant effects that would 
have been expected to affect unpunished responding.  
 In addition, the study in which the punishing effects of nicotine were attenuated 
by delaying the delivery of response-dependent nicotine such that rates of nicotine self-
administered increased suggest that a punisher is most effective when it is delivered 
immediately upon a response-contingent behavior. Therefore manipulation of the 
contiguity between a response and its consequence may be used as a control in single 
operant conditions to determine whether decreases in behavior are due to a drug’s 
punishing and/or direct suppressant effects. In theory, since punishment is a decrease 
in responding due to a learned contingency, then manipulation of the relationship of the 
response and its consequence should affect punishment. Whereas manipulation of 
variables such as delay should not affect the direct suppressant effects since 
decreases in responding are unconditioned. Lastly, the study in which response-
independent nicotine was delivered may be useful in determining a rate-limiting dose of 
drugs in which operant behavior can be evaluated without concerns regarding 
unconditioned effects. Therefore, the procedures described herein contribute to the 
study of the behavioral effects of drugs by providing procedures in which the punishing 
effects of drugs may be evaluated thoroughly.  
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Differentiating the aversive and reinforcing effects of IV nicotine 
pharmacologically  
 The psychoactive effects of nicotine are believed to be mediated predominately 
through its agonist actions on the various neuronal nicotinic acetylcholine receptors 
(nAChRs), which differ in subunit structure, kinetic and pharmacological properties, and 
distribution within the nervous system (see Gotti and Clementi 2004; Taly et al. 2009). 
Accordingly, it has been proposed that each of these nAChR subtypes may also have 
unique roles in mediating the behavioral effects of nicotine that contribute to tobacco 
addiction (see Picciotto and Kenny 2013). Although the roles for several of the individual 
nicotinic receptor subtype(s) in mediating the behavioral effects of nicotine have yet to 
be elucidated, substantial evidence from behavioral studies using both pharmacological 
and genetic techniques indicate the α4β2* nAChR subtype is involved in mediating the 
reinforcing effects of nicotine (see Benowitz 2008; Picciotto and Kenny 2013). 
Interestingly, antagonist studies with DHβE, a selective α4β2* nAChR subtype 
antagonist (Williams and Robinson, 1984; Sabey et al. 1999; Shoaib et al. 2000) found 
that DHβE was able to attenuate both nicotine-induced conditioned taste aversion 
(Shoaib et al. 2000; Gommans et al. 2000) and nicotine-induced conditioned place 
aversion (Laviolette and van der Kooy 2003) in rats. While a drawback of both 
conditioned taste aversion and conditioned place aversion is that the experimenter 
administers the nicotine, both have been argued to provide useful information on the 
aversive effects of nicotine. With conditioned place aversion procedures, animals are 
tested for the development of conditioned avoidance for environments distinctly paired 
with nicotine. It has been argued that avoidance behavior and decreased time spent in 
a nicotine-paired environment is a measure of the aversive effects of nicotine. Similarly, 
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it is argued that conditioned taste aversion is a measure the nicotine’s capability to 
serve as an aversive conditioned stimulus that result in avoidance of tastes paired with 
its administration. Accordingly, these findings suggest that the α4β2* nAChR subtype 
may also be involved in mediating the punishing effects of nicotine. However, the 
antagonist studies with mecamylamine and DHβE presented in Chapter 4 provide 
evidence to suggest that while the punishing effects of IV nicotine are mediated by 
nAChRs, they are not mediated by the α4β2* nAChR subtype, as demonstrated by the 
failure of DHβE to block the punishing effects of nicotine. These findings are important 
because while it is unclear which nAChR subtype(s) are involved in mediating the 
punishing effects of IV nicotine, they indicate that the aversive and reinforcing effects of 
nicotine may be differentiated pharmacologically.  
 In addition to the proposed role of the α4β2* nAChR subtype in mediating the 
reinforcing effects of nicotine (Corrigall et al. 1994; Watkins et al. 1999; Mansbach et al. 
2000; Liu et al. 2007; Le Foll et al. 2009) it has been reported that the α4β2* nAChR 
subtype is involved in mediating the discriminative stimulus effects of nicotine, which 
are believed to promote nicotine self-administration in both humans and non-human 
subjects because the ability to perceive and identify characteristic interoceptive effects 
of nicotine encourages the development of the such behaviors (see Stolerman 1992; 
Smith and Stolerman 2009). However, it is unclear whether the discriminative stimulus 
effects of nicotine mediated by the α4β2* nAChR subtype are involved in the punishing 
effects of nicotine. Interestingly, Jutkiewicz et al. (2011), found that while DHβE 
antagonized the discriminative effects of nicotine in rats, it was less effective at 
antagonizing the high dose of nicotine (1.78 mg/kg; s.c.) compared to the low dose 
(0.32 mg/kg; s.c.). Schild analyses of DHβE suggested that different nAChRs subtypes 
might be mediating the stimulus effects of large and small doses of nicotine. 
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Accordingly, while the α4β2* nAChR subtype is involved in mediating the discriminative 
stimulus effects of nicotine that are presumed to be related to the reinforcing effects of 
nicotine, it is possible that the other nAChR subtype(s), while unknown, are involved in 
mediating the discriminative stimulus effects that are related to the aversive effects of 
nicotine. 
 While the identification of the nAChR subtype (s) that mediates the punishing 
effects of nicotine remains to be established, there is evidence to suggest that the 
nAChRs that mediate the aversive effects of nicotine are located in the CNS. For 
example, Spealman (1983) found that treatment with hexamethonium, a nicotinic 
antagonist with primarily peripheral effects, was not able to attenuate the aversive 
effects of nicotine that maintained responding to postpone delivery of IV nicotine in 
squirrel monkeys, whereas mecamylamine could. In agreement, studies using genetic 
techniques found that mice with deletion of the α5 nAChR subunit, [which is 
predominately expressed in brain regions that include the habenulo-interpeduncular 
pathways, VTA and substantia nigra (Marks et al. 1992)] increased nicotine self-
administration at unit doses of nicotine found on the descending limb, but not the 
ascending limb, of the typical inverted U-shaped dose-response curve of nicotine self-
administration (Fowler et al. 2011). It has been proposed that doses of nicotine found 
on the descending limb of a typical inverted U-shaped dose-response curve have 
aversive properties that limit rates of responding (e.g., Katz 1989; Rose and Corrigall 
1997). This suggests that the nAChRs that are composed of the α5 subunit may be 
involved in mediating the aversive effects of nicotine. While it is recognized that a 
limitation of genetic studies is the possibility of adaptations in neural circuitry that may 
affect the interpretation of the behavioral effects of nicotine, they are useful when 
pharmacological agents to study individual nAChR subtype are limited. Interestingly, an 
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increased vulnerability to tobacco addiction has been found in humans with 
polymorphisms in the α5 nAChR subunit gene, which results in decreased function of 
the subunit (Bierut et al. 2008; Kuryatov et al. 2011). Polymorphisms in the α5 nAChR 
subunit has been associated with an increased risk of developing lung cancer and 
chronic obstructive pulmonary pathway in smokers (Wang et al. 2010; Amos et al. 2008; 
Le Marchand et al. 2008), which may reflect greater exposure to carcinogens from 
greater smoking (Macqueen et al. 2014).  
 
Limitation of findings 
 While studies have shown that nicotine can produce reinforcing effects (e.g., 
Corrigall and Coen 1989; Shoaib et al. 1997; Watkins et al. 1999; Chaudhri et al. 2005), 
the findings reported herein show that nicotine can also produce aversive effects, 
demonstrating that the behavioral effects of nicotine are complex. Presumably it is the 
interaction/balance of these independent effects that ultimately determine rates of 
nicotine self-administration in both humans and non-humans. Accordingly, a procedure 
in which both the reinforcing and aversive effects of nicotine can be detected within the 
same subjects would help determine the relative contributions of each of these effects 
in drug self-administration. However, since the effects of individual nicotine injections 
were not evaluated independent of sucrose delivery in the studies reported in Chapter 3 
or Chapter 4, it is unclear whether the reinforcing effects of sucrose alone, or a 
combination of the reinforcing effects of sucrose and nicotine maintained responding 
on levers that delivered nicotine with sucrose. Therefore, a limitation of the findings 
reported in Chapter 3 and 4 is that it is unclear whether punishment by nicotine is a 
result of the aversive effects of nicotine alone, and/or the reinforcing effects of nicotine 
being relatively weak compared to its aversive effects, or whether lever responding that 
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results in nicotine injections is being maintained by the sucrose delivery that is paired 
with its delivery. However, a separate experiment using the same schedules of 
reinforcement (FR 1, with 120 s ITI, daily-90 min sessions) found that nicotine injections 
alone could not maintain lever responding above responding on levers that had no 
schedule consequence (Figure A1.1), which suggest that punishment is more likely a 
result of the aversive effects of nicotine alone, and that responding on the lever that 
results in nicotine injections is being maintained by the sucrose that is delivered with it 
concurrently. 
 Alternatively, it could also be argued that the procedures used herein may not 
provide a sensitive measure of the reinforcing effects of drugs.  However these 
procedures have been used to demonstrate the reinforcing effects of the fast- and 
short-acting mu opioid receptor agonist remifentanil (Figure A1.2). In studies examining 
the effects of remifentanil, it was established that response-contingent IV remifentanil 
paired with sucrose delivery was more reinforcing than delivery of sucrose alone, and it 
was shown that injections of 10.0 µg/kg remifentanil were more reinforcing than 
sucrose. This demonstrates that the operant procedures used in Chapter 3 and Chapter 
4 can detect the reinforcing effects of drugs such as remifentanil, but suggest that 
these procedures do not provide a sensitive measure of the reinforcing effects of 
nicotine. This is not surprising since it has been noted that the reinforcing strength of 
nicotine is considered weak relative to other drugs of abuse (Griffiths et al. 1979; 
Dougherty et al. 1981; Henningfield and Goldberg 1983b; Collins 1990), and that 
establishing the reinforcing effects of nicotine remains difficult in controlled studies (see 
Le Foll and Goldberg 2009). 
 Since drugs such as nicotine can produce both reinforcing and aversive effects, 
and it is proposed that the relative contribution of these effects determine drug-taking 
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behaviors, then it would be advantageous to examine both effects in the same group of 
subjects. For instance, it would be predicted that subjects that were more sensitive to 
the aversive effects would be less sensitive to the reinforcing effects and vice versa. 
Since there are currently no procedures in which both the reinforcing and aversive 
effects of nicotine can be measured, it may be necessary to use multiple procedures to 
assess the effects of nicotine. Therefore, while the operant procedures used to study 
the punishing effects of nicotine reported herein may not provide a sensitive measure of 
the reinforcing effects of nicotine; it may be used in combination with self-
administration procedures that are known to be sensitive to the reinforcing effects to 
provide a better understanding of drug-taking behaviors. 
 
Consideration of other effects of nicotine that may affect self-administration 
 While discussion of the effects of nicotine that may affect rates of self-
administration have been largely focused on the reinforcing and aversive effects of 
nicotine, consideration of other effects could also contribute to the understanding of 
nicotine-taking behaviors. For instance, administration of nicotine in humans through 
cigarettes and IV injections has been known to increase heart rate and blood pressure 
in a dose-dependent manner (e.g., Koch et al 1980; Soria et al 1996; Rose et al. 2000), 
and in some instances these cardiovascular effects coincide with dose-dependent 
increases in subjective ratings of “drug liking” in participants with histories of drug 
abuse and cigarette smoking (Henningfrield et al. 1985; Soria et al. 1996; Garrett and 
Griffths 1997). It has also been noted that although smokers and nonsmokers displayed 
significant increases in blood pressure and heart rate after nicotine administration, a 
difference between heart rate measured at later times was greater in nonsmokers that 
also reported they were less likely to “use [nicotine] again” (Soria et al. 1996). 
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Cardiovascular effects may therefore contribute to punishment by nicotine.  
 Other effects of nicotine worth considering are its commonly reported stimulant 
and anxiolytic effects that may induce pleasure and reduce stress and anxiety in 
humans (see Picciotto et al. 2002, Benowitz 2010). For instance, high rates of smoking 
have been observed among patients with affective disorders (Breslau 1995) such that 
the rate of smoking in individuals with affective disorders is more than double the rate in 
the general population (Kalman et al. 2005). Interestingly it has been reported that 
nicotine can produce antidepressant effects in both smokers and non-smokers (Salin-
Pascual et al. 1996). Whereas cessation of smoking has been known to induce 
withdrawal symptoms that include irritability, depressed mood, and anxiety (Hughes 
and Hatsukami 1986). Behavioral models of anxiety and depression in rodents suggest 
that nicotine can have both anxiolytic and antidepressant effects (see File et al. 2000). 
Therefore, consideration of these effects in relation to the reinforcing and aversive 
effects may contribute to a better understanding of smoking behavior in humans. 
 
Aversive effects of nicotine: implications in understanding tobacco use in humans  
 It has been argued that while nicotine has reinforcing effects, it differs from other 
drugs of abuse because its reinforcing strength (i.e., likelihood that nicotine will function 
as a reinforcer under varying experimental conditions) is relatively weak (Griffiths et al. 
1979; Dougherty et al. 1981; Henningfield and Goldberg 1983b; Collins 1990). In 
response to these observations, theories of nicotine reinforcement have proposed that 
nicotine may reinforce tobacco use through its primary reinforcing effects (albeit weak 
relative to other drugs of abuse), its secondary reinforcing effects in which neutral 
stimuli become conditioned reinforcers through Pavlovian conditioning (Rose and Levin 
1991; Balfour 2004) and/or through its reinforcement enhancer effects (i.e., stimulus 
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effects that increase the incentive value of accompanying stimuli that are either 
conditioned or unconditioned reinforcers) (Chaudhri et al. 2006). While these theories 
may explain how nicotine, a relatively weak reinforcer, can maintain robust self-
administration and tobacco-taking behaviors, a limitation of these theories is that they 
do not take into account that nicotine can also produce aversive effects.  
 Accordingly it has been proposed by some and us that self-administration of 
nicotine may be a function of the interaction between the reinforcing and aversive 
effects of the drug (Stolerman and D’Mello 1981; Katz 1989; Lynch and Carroll 2001; 
Riley 2011). It is well known that IV nicotine can produce negative and/or positive 
subjective effects concurrently in both smokers and non-smokers (see Kalman 2002; 
Kalman and Smith 2005), and it is believed that people’s sensitivity to each of these 
effects is a predictor of whether people who experiment with nicotine through tobacco 
become regular smokers (see Pomerleau et al. 1993). Many people experience noxious 
effects such as nausea and dizziness on their initial experience with tobacco (Kozlowski 
and Harford 1976; Pomerleau 1995), and tolerance to these negative subjective effects 
with repeated exposure to nicotine has been proposed as mechanism in which people 
become smokers (see Pomerleau et al. 1993). For instance, it has been shown that 
nicotine can produce greater positive subjective effects and less negative effects in 
smokers than in non-smokers, such that these smokers were more likely to “use 
[nicotine] again” (Soria et al. 1996). In cigarette smoking cocaine users, it has been 
reported that IV cocaine produced greater positive subjective effects than IV nicotine, 
whereas nicotine produced greater negative subjective effects (Jones et al. 1999). 
Additionally, it was found that the cigarette smoking cocaine users were willing to forgo 
twice as much money for an injection of IV cocaine compared to nicotine in a money 
versus drug choice situation. This demonstrates that nicotine and cocaine can be 
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differentiated by their subjective and reinforcing effect. Therefore, while the reinforcing 
effects of nicotine contributes to an understanding of nicotine reinforcement, the 
degree to which nicotine is reinforcing may also reflect an interaction with the aversive 
effects that function to limit self-administration of nicotine. 
 Alternatively, it has also been proposed that unconditioned direct suppressant 
effects which include but are not limited to non-specific disruptions in behavior that 
decrease responding because animal are unable to respond may also influence rates of 
drug self-administration (Katz 1989; Carroll and Bickel 1998; Skjoldager et al 1991). This 
may be relevant to nicotine since it has been noted that doses of nicotine that are self-
administered (and typically fall on the descending limb of the inverted U-shaped dose 
response curve) can also produce noxious effects such as emesis in squirrel monkeys 
(Goldberg et al. 1983) and seizures in rats (Corrigall, unpublished observations). In 
addition, it is proposed that rates of self-administration may be influenced by satiation 
of drug effects, in which the animal responds according to an optimal drug level or drug 
effect (Yokel 1987; Katz 1989). However, the overall shape of the dose-response curve 
for IV nicotine self-administration in animals tends to differ from other drugs of abuse 
such as cocaine and opiates such that rates at which self-administration of nicotine 
appears to not change as the dose increases, making the dose-response curve more 
flat (Dia et al 1989; Corrigall and Coen 1991). This pattern of self-administration of 
behavior in which responding seems to be insensitive to dose occurs across a variety of 
animal species, and schedules of reinforcement such as fixed ratio, fixed interval, or 
progressive ratio (Goldberg et al. 1981; Risner and Goldberg 1983; Corrigall and Coen 
1989). Therefore, while changes in responding are seemingly related to dose, it may be 
that other effects are contributing to rates of self-administration. Nonetheless, 
consideration of the possible direct effects and/or satiation may be useful in explaining 
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individual differences in the rates at which cigarettes are smoked among smokers. 
 
Tobacco Addiction is an ongoing problem 
 In January of 2014, the Surgeon General released a new report on the health 
consequences of smoking. The release of the 2014 report marks the 50th anniversary of 
the 1964 report, which is arguably one of the most influential publications responsible 
for bringing public awareness to the health consequences of tobacco smoking. Since 
the release of the 1964 report, the prevalence of cigarette smoking among adults in the 
United States has declined from 42% in 1965 to 18% in 2012 (US Department of Health 
and Human Services 2014). However, despite the “50 years of Progress” in tobacco-
related research and policy, over 40 million Americans continue to smoke, and it is 
estimated that over 400,000 will die every year from smoking-related disease.  The 
2014 report also suggests that cigarettes today are more harmful than they were fifty 
years ago. Today’s smokers have a higher risk of developing lung cancer than smokers 
in 1964, despite smoking fewer cigarettes (due in part to the changes in the 
composition and design of cigarettes, such as the use of ventilated filters that can lead 
to more inhalation of lethal materials). Therefore, while progress has been made, 
tobacco addiction is still a serious problem, and the use of tobacco remains a leading 
cause of preventable disease and premature death in the United States and other 
countries.  
 
Future studies 
  Of the people that try cigarette smoking, it is estimated that only 20 -25% of 
them become smokers (Johnston et al. 2007). This suggests that while the reinforcing 
effects of nicotine may contribute to development and maintenance of cigarette 
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smoking in 75-80 % of the people who try cigarette smoking, there may be individual 
differences, which may predict whether a person is more vulnerable to smoking 
addiction than others. Since it has been proposed herein that the aversive effects of 
nicotine may prevent or limit self-administration of nicotine, future studies examining 
the effects of nicotine in humans should include an examination of the aversive effects 
of nicotine and determinants that contribute to punishment. 
 It is has been proposed that certain people become smokers depending on their 
sensitivity to the aversive effects of nicotine, such that people who are more sensitive 
are less likely to become regular smokers (see Pomerleau et al. 1993). This suggests 
that people with less sensitivity to the aversive effects of nicotine may be more 
vulnerable to developing tobacco addiction. In keeping with this, smokers with 
polymorphisms in the α5 nAChR subunit gene that results in a decrease function of the 
subunit (Bierut et al. 2008; Kuryatov et al. 2011) have been shown to smoke more 
cigarettes than smokers without the polymorphism (Macqueen et al. 2014). Since it has 
been proposed that the α5 nAChR subunit may be involved in mediating the aversive 
effects of nicotine (Fowler et al. 2011), it may be useful to examine whether people with 
polymorphisms in the α5 nAChR subunit gene are less sensitive to the aversive effects 
of nicotine. Additionally, development of antagonists that are selective at the α5 subunit 
may be useful in determining the precise role of nAChRs containing the α5 subunit in 
tobacco smoking, which may have implications on how to prevent and/or treat tobacco 
addiction. In theory, it is possible that a pharmacotherapy that selectively increases the 
aversive effects of nicotine while decreasing the reinforcing effects may be useful in the 
cessation of smoking.  
 Lastly, tobacco use typically begins in childhood or adolescence, such that it 
has been reported that 80% of smokers begin smoking by 18 years of age, and that 
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there is an increased risk of developing tobacco addiction in people who experiment at 
an earlier age (Lynch and Bonnie 1994). Exposure to nicotine in adolescence may have 
differential effects in the development and maintenance of nicotine self-administration 
compared to exposure in adulthood, because adolescence represents a unique period 
in which there may be an increased vulnerability to the reinforcing effects of nicotine 
(see Slotkin 2001; Barron et al. 2005). Therefore, future studies using a model of 
adolescent nicotine punishment in rats to examine whether or how the aversive effects 
of nicotine may affect nicotine-self administration may provide information on how 
tobacco addiction may differentially develop in adolescents compared to adults. These 
studies could contribute to an understanding why young people who try cigarettes are 
more likely to develop an addiction.  
 
Conclusions 
 Examining the behavioral effects of nicotine has been crucial in understanding 
tobacco addiction. However, the effects of nicotine that contribute to tobacco-
addiction are complex and remain poorly understood. The findings reported herein and 
in other studies show that nicotine is a complex pharmacological compound that can 
produce divergent effects that may be differentiated pharmacologically. Therefore, 
while it is recognized that the reinforcing effects of nicotine contributes to the 
development and maintenance of the abuse of nicotine-containing tobacco products 
(Young and Herling 1986; Ator and Griffths 2003), these effects alone may not 
determine whether nicotine is self-administered, or the rates in which nicotine is self-
administered. Examining the aversive effects of nicotine may contribute to a better 
understanding of how nicotine can control behavior. Consideration of both the 
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reinforcing and aversive effects of nicotine may have practical implications in the 
treatment and prevention of tobacco addiction.  
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Figure A1.1 Responding on levers that delivered either sucrose, IV nicotine, IV 
saline or nothing. Each graph displays data from individual groups that differ by the 
consequence of responding on lever 2 (a) IV saline injection (b) IV 0.03 mg/kg nicotine 
injection across sessions 1-5 (n=5-6 per group). Closed and open symbols represent 
the mean (±SEM) responses made on lever 1 and lever 2, respectively. Legends next to 
the symbols listed in the table indicate the consequences of responding on lever 1 and 
lever 2 across sessions.  
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Figure A1.2 Effects of pairing remifentanil injection with sucrose delivery on lever 
responding. Each graph displays data from individual groups that differ by the dose of 
IV remifentanil (remi) injection paired with sucrose (suc) delivery across sessions 6-15 
(a) 3.2 µg/kg  (b) 10.0 µg/kg (n=8 per group). Closed and open symbols represent the 
mean (±SEM) responses made on lever 1 and lever 2, respectively. Legends next to the 
symbols listed in the table indicate the consequences of responding on lever 1 and 
lever 2 across sessions. 
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